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Preamble and Transition to ACC/AHA 
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC) 
and the American Heart Association (AHA) are to prevent 
cardiovascular diseases; improve the management of people 
who have these diseases through professional education and 
research; and develop guidelines, standards, and policies 
that promote optimal patient care and cardiovascular health. 
Toward these objectives, the ACC and AHA have collaborated 
with the National Heart, Lung, and Blood Institute (NHLBI) 
and stakeholder and professional organizations to develop 
clinical practice guidelines for assessment of cardiovascular 
risk, lifestyle modifications to reduce cardiovascular risk, 
management of blood cholesterol in adults, and management 
of overweight and obesity in adults.
In 2008, the NHLBI initiated these guidelines by sponsoring 
rigorous systematic evidence reviews for each topic by expert 
panels convened to develop critical questions (CQs), interpret 
the evidence, and craft recommendations. In response to the 
2011 report from the Institute of Medicine on the develop-
ment of trustworthy clinical guidelines,1 the NHLBI Advisory 
Council recommended that the NHLBI focus specifically on 
reviewing the highest-quality evidence and partner with other 
organizations to develop recommendations.2,3 Accordingly, in 
June 2013 the NHLBI initiated collaboration with the ACC and 
AHA to work with other organizations to complete and pub-
lish the 4 guidelines noted above and make them available to 
the widest possible constituency. Recognizing that the Expert 
Panels/Work Groups did not consider evidence beyond 2011 
(except as specified in the methodology), the ACC, AHA, and 
collaborating societies plan to begin updating these guidelines 
starting in 2014.
The joint ACC/AHA Task Force on Practice Guidelines 
(Task Force) appointed a subcommittee to shepherd this tran-
sition, communicate the rationale and expectations to the writ-
ing panels and partnering organizations, and expeditiously 
publish the documents. The ACC/AHA and partner organi-
zations recruited a limited number of expert reviewers for 
fiduciary examination of content, recognizing that each docu-
ment had undergone extensive peer review by representatives 
of the NHLBI Advisory Council, key federal agencies, and 
scientific experts. Each writing panel responded to comments 
from these reviewers. Clarifications were incorporated where 
appropriate, but there were no substantive changes because 
the bulk of the content was undisputed.
Although the Task Force led the final development of 
these prevention guidelines, they differ from other ACC/
AHA guidelines. First, as opposed to an extensive compen-
dium of clinical information, these documents are signifi-
cantly more limited in scope and focus on selected CQs on 
each topic, based on the highest-quality evidence available. 
Recommendations were derived from randomized trials, meta-
analyses, and observational studies evaluated for quality and 
were not formulated when sufficient evidence was not avail-
able. Second, the text accompanying each recommendation 
is succinct, summarizing the evidence for each question. The 
Full Panel/Work Group Reports include more detailed infor-
mation about the evidence statements that serve as the basis 
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for recommendations. Third, the format of the recommenda-
tions differs from other ACC/AHA guidelines. Each recom-
mendation has been mapped from the NHLBI grading format 
to the ACC/AHA Classification of Recommendation/Level of 
Evidence (COR/LOE) construct (Table 1) and is expressed in 
both formats. Because of the inherent differences in grading 
systems and the clinical questions driving the recommenda-
tions, alignment between the NHLBI and ACC/AHA formats 
is in some cases imperfect. Explanations of these variations 
are noted in the recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by the 
writing panels to manage relationships of authors with indus-
try and other entities (RWI) are outlined in the methods section 
of each panel report. These policies were in effect when this 
effort began in 2008 and throughout the writing process and 
voting on recommendations, until the process was transferred 
to ACC/AHA in 2013. In the interest of transparency, the 
ACC/AHA requested that panel authors resubmit RWI disclo-
sures as of July 2013. Relationships relevant to this guideline 
are disclosed in Appendix 1. None of the ACC/AHA expert 
reviewers had relevant RWI (Appendix 2). See Appendix 3 for 
a list of abbreviations used in the guideline.
Systematic evidence reports and accompanying summary 
tables were developed by the expert panels and NHLBI. 
The guideline was reviewed by the ACC/AHA Task Force 
and approved by the ACC Board of Trustees, and the AHA 
Science Advisory and Coordinating Committee. In addition, 
ACC/AHA sought endorsement from other stakeholders, 
including professional organizations. It is the hope of the writ-
ing panels, stakeholders, professional organizations, NHLBI, 
and Task Force that the guidelines will garner the widest pos-
sible readership for the benefit of patients, providers, and the 
public health.
These guidelines are meant to define practices that meet 
the needs of patients in most circumstances and are not a 
replacement for clinical judgment. The ultimate decision 
about care of a particular patient must be made by the 
healthcare provider and patient in light of the circum-
stances presented by that patient. As a result, situations 
might arise in which deviations from these guidelines may 
be appropriate. These considerations notwithstanding, in 
caring for most patients, clinicians can employ the recom-
mendations confidently to reduce the risks of atheroscle-
rotic cardiovascular disease (ASCVD) events.
See Tables 1a and 1b for an explanation of the NHLBI rec-
ommendation grading methodology.
1. Introduction
1.1. Organization of the Panel
The Blood Cholesterol Expert Panel (Expert Panel) was origi-
nally convened as the Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel IV) appointed by the NHLBI. The Expert 
Panel was composed of 13 members and 3 ex-officio mem-
bers, which included primary care physicians, cardiologists, 
endocrinologists, and experts in clinical lipidology, clinical tri-
als, cardiovascular epidemiology and nutrition, and guideline 
development. The Expert Panel chair asked all panel members 
to disclose any conflict-of-interest information to the full 
panel in advance of the deliberations; members with conflicts 
were asked to recuse themselves from voting on any aspect of 
the guideline for which a conflict might exist. All 16 members 
of the NHLBI Adult Treatment Panel IV Panel transitioned to 
the ACC/AHA guideline Expert Panel. Independent contrac-
tors performed the systematic review with the assistance of 
the Expert Panel and provided methodological guidance to the 
Expert Panel.
1.2. Document Review and Approval
A formal peer review process was initially completed under 
the auspices of the NHLBI and included 23 expert reviewers 
and representatives of federal agencies. This document was 
also reviewed by 4 expert reviewers nominated by the ACC 
and the AHA when the management of the guideline transi-
tioned to the ACC/AHA. The ACC and AHA reviewers’ RWI 
information is published in this document (Appendix 2).
This document was approved for publication by the govern-
ing bodies of the ACC and AHA and endorsed by the American 
Academy of Physician Assistants, American Association of 
Cardiovascular and Pulmonary Rehabilitation, American 
Pharmacists Association, American Society for Preventive 
Cardiology, Association of Black Cardiologists, Preventive 
Cardiovascular Nurses Association, and WomenHeart: The 
National Coalition for Women with Heart Disease.
1.3. Scope of Guideline
This guideline is based on the Full Panel Report, which is 
provided as an online-only data supplement to the guide-
line. The Full Panel Report contains background and addi-
tional material related to content, methodology, evidence 
synthesis, rationale, and references and is supported by the 
NHLBI Systematic Evidence Review, which can be found 
at http://www.nhlbi.nih.gov/guidelines/cholesterol/ser/. 
Table 2 provides an overview to facilitate understanding 
what is new in the present guideline.
The Expert Panel was charged with using data from ran-
domized controlled trials (RCTs) and systematic reviews and 
meta-analyses of RCTs to update the clinical practice rec-
ommendations for the treatment of blood cholesterol levels 
to reduce ASCVD risk. For this guideline, ASCVD includes 
coronary heart disease (CHD), stroke, and peripheral arterial 
disease, all of presumed atherosclerotic origin. These recom-
mendations are intended to provide a strong, evidence-based 
foundation for the treatment of cholesterol for the primary and 
secondary prevention of ASCVD in women and men.
Because RCT data were used to identify those most likely 
to benefit from cholesterol-lowering statin therapy, the recom-
mendations will be of value to primary care clinicians as well as 
specialists concerned with ASCVD prevention. Importantly, the 
recommendations were designed to be easy to use in the clini-
cal setting, facilitating the implementation of a strategy of risk 
assessment and treatment focused on the prevention of ASCVD. 
The present guideline is intended to address treatment of adults 
(≥21 years of age) to complement the NHLBI cardiovascular 
health risk-reduction guideline for children and adolescents.4
The members of the Expert Panel acknowledge the 
important contributions arising from decades of genetic and 
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biochemical studies, observational epidemiological and eco-
logical studies, and in vitro and animal experiments that asso-
ciated higher low-density lipoprotein cholesterol (LDL-C) 
levels with greater ASCVD risk. These studies provided the 
rationale for RCTs, which in turn demonstrated that lowering 
cholesterol levels reduced ASCVD events and thereby estab-
lished a central, causal role of atherogenic cholesterol-con-
taining lipoprotein particles, particularly LDL, in the genesis 
of CHD and ASCVD.
Other strategies for using drug therapy to reduce ASCVD 
events have been advocated, including treat-to-cholesterol 
target, lowest-is-best, and risk-based treatment approaches. 
However, only 1 approach has been evaluated in multiple 
RCTs—the use of fixed doses of cholesterol-lowering drugs to 
reduce ASCVD risk. Because the overwhelming body of evi-
dence came from statin RCTs, the Expert Panel appropriately 
focused on these statin RCTs to develop evidence-based 
guidelines for the reduction of ASCVD risk. We recognize 
that this represents a significant departure from current strat-
egies. This should not come as a surprise to clinicians. The 
recent guideline on heart failure has changed long-standing 
paradigms on the basis of the evidence, and this guideline 
does as well.5 Future RCTs will be needed to determine the 
optimal treatment strategy to provide the greatest reduction in 
ASCVD events with best margin of safety.
The Expert Panel acknowledges that our process did not 
provide for a comprehensive approach to the detection, evalu-
ation, and treatment of lipid disorders as was done in the prior 
Adult Treatment Panel III Report.6 However, the present guide-
line was never intended to be a comprehensive approach to 
lipid management for purposes other than ASCVD risk reduc-
tion. A limited number of expert opinion recommendations 
Table 1. Applying Classification of Recommendation and Level of Evidence
 
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines 
do not lend themselves to clinical trials. Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is 
useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior 
myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve 
direct comparisons of the treatments or strategies being evaluated.
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were made only when RCT evidence was not present and after 
a thorough consideration of what the Expert Panel had learned 
from the RCTs. For the many questions about complex lipid 
disorders that are beyond the scope of our systematic evidence 
review, or for which little or no RCT data are available, it is 
anticipated that clinicians with lipid expertise can contribute 
to their management.
1.4. Methodology and Evidence Review
Although the Expert Panel was convened before the Institute 
of Medicine reports on practice guidelines, our evidence-
based process followed most of the standards from the 
Institute of Medicine report, “Clinical Practice Guidelines We 
Can Trust.”1 The systematic review was limited to RCTs with 
ASCVD outcomes and systematic reviews and meta-analyses 
of RCTs with ASCVD outcomes. Observational studies and 
those with <18 months (CQ1 and CQ2) or <12 months (CQ3) 
of follow-up were excluded. Support was provided by a meth-
odology contractor and a systematic review and general sup-
port contractor and included the following steps:
•	 The Expert Panel constructed CQs relevant to clinical 
practice.
•	 The Expert Panel identified (a priori) inclusion/exclu-
sion criteria for each CQ.
•	 An independent contractor developed a literature 
search strategy, based on inclusion/exclusion criteria, 
for each CQ.
•	 An independent contractor executed a systematic elec-
tronic search of the published literature from relevant 
Table 1a. NHLBI Grading of the Strength of Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net benefit‡  
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net benefit  
is moderate to substantial, or there is high certainty that the net 
benefit is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that there  
is a small net benefit.
D Recommendation against
There is at least moderate certainty based on evidence that there  
 is no net benefit or that risks/harms outweigh benefits.
E Expert opinion (“There is insufficient evidence or evidence is unclear  
or conflicting, but this is what the Work Group recommends.”)
Net benefit is unclear. Balance of benefits and harms cannot be 
determined because of no evidence, insufficient evidence, unclear 
evidence, or conflicting evidence, but the Work Group thought it  
was important to provide clinical guidance and make a 
recommendation. Further research is recommended in this area.
N No recommendation for or against (“There is insufficient evidence  
or evidence is unclear or conflicting.”)
Net benefit is unclear. Balance of benefits and harms cannot be 
determined because of no evidence, insufficient evidence, unclear 
evidence, or conflicting evidence, and the Work Group thought  
no recommendation should be made. Further research is 
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned 
with the quality of the evidence; however, under some circumstances, there 
may be valid reasons for making recommendations that are not closely aligned 
with the quality of the evidence (eg, strong recommendation when the evidence 
quality is moderate, such as smoking cessation to reduce cardiovascular 
disease risk or ordering an ECG as part of the initial diagnostic work-up for a 
patient presenting with possible MI). Those situations should be limited and the 
rationale explained clearly by the Work Group.
†Net benefit is defined as benefits minus risks/harms of the service/
intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, 
National Heart, Lung, and Blood Institute.
Table 1b. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
•	Well-designed, well-executed‡ RCT that adequately  
 represent populations to which the results are applied and 
directly assess effects on health outcomes.
•	Meta-analyses of such studies.
Highly certain about the estimate of effect. Further research is 
unlikely to change our confidence in the estimate of effect.
>High
•	RCT with minor limitations‡ affecting confidence in,  
or applicability of, the results.
•	Well-designed, well-executed nonrandomized  
 controlled studies§ and well-designed, well-executed 
observational studies‖.
•	Meta-analyses of such studies.
Moderately certain about the estimate of effect. Further 
research may have an impact on our confidence in the 
estimate of effect and may change the estimate.
>Moderate
•	RCT with major limitations.
•	Nonrandomized controlled studies and observational  
 studies with major limitations affecting confidence in,  
or applicability of, the results.
•	Uncontrolled clinical observations without an  
 appropriate comparison group (eg, case series,  
case reports).
•	Physiological studies in humans.
•	Meta-analyses of such studies.
Low certainty about the estimate of effect. Further research 
is likely to have an impact on our confidence in the 
estimate of effect and is likely to change the estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (eg, 
jumping from airplanes or tall structures), can represent high- or moderate-
quality evidence. In such cases, the rationale for the evidence rating exception 
should be explained by the Work Group and clearly justified.
†“Well-designed, well-executed” refers to studies that directly address the 
question; use adequate randomization, blinding, and allocation concealment; are 
adequately powered; use intention-to-treat analyses; and have high follow-up rates.
‡Limitations include concerns with the design and execution of a study that 
result in decreased confidence in the true estimate of the effect. Examples 
of such limitations include but are not limited to: inadequate randomization, 
lack of blinding of study participants or outcome assessors, inadequate power, 
outcomes of interest that are not prespecified for the primary outcomes, 
low follow-up rates, and findings based on subgroup analyses. Whether the 
limitations are considered minor or major is based on the number and severity 
of flaws in design or execution. Rules for determining whether the limitations 
are considered minor or major and how they will affect rating of the individual 
studies will be developed collaboratively with the methodology team.
§Nonrandomized controlled studies refer to intervention studies where 
assignment to intervention and comparison groups is not random (eg, quasi-
experimental study design).
‖Observational studies include prospective and retrospective cohort, case-
control, and cross-sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, 
randomized controlled trials.
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bibliographic databases for each CQ. The date range 
for the overall literature search was January 1, 1995, 
through December 1, 2009. However, RCTs with hard 
ASCVD outcomes of myocardial infarction (MI), stroke, 
and cardiovascular death published after that date range 
were eligible for consideration until the Expert Panel 
began deliberations on relevant recommendations.
•	 RCTs that met the inclusion criteria and were indepen-
dently graded as fair or good quality were included in the 
evidence tables for the consideration of the Expert Panel. 
RCTs that were graded as poor quality were excluded.
•	 With the assistance of independent methodologists, this 
evidence base was used to develop a series of evidence 
statements graded on the level of the evidence (high, 
medium, or low).
•	 The Expert Panel then synthesized the evidence state-
ments into treatment recommendations/summaries 
graded as A (strong), B (moderate), C (weak), D (recom-
mend against), E (expert), and N (no recommendation).
•	 The final evidence statements and treatment recommen-
dations were approved by at least a majority of voting 
members of the Expert Panel.
•	 Guideline implementability appraisals, planned and 
coordinated by the NHLBI Implementation Work Group, 
were performed to identify and address barriers to guide-
line implementation.
In addition, the Expert Panel was able to include major RCTs 
and meta-analyses of RCTs published through July 2013 in 
our discussion and as part of the process of determining ACC/
AHA grading of the NHLBI expert-level recommendations.
2. Overview of the Guideline
The RCTs identified in the systematic evidence review 
indicated a consistent reduction in ASCVD events from 
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tor (statin) therapy in secondary- and primary-prevention 
populations, with the exception of no ASCVD event reduc-
tion when statin therapy was initiated in those with New York 
Heart Association class II to IV heart failure or those receiving 
maintenance hemodialysis. The RCTs either compared fixed 
doses of statins with placebo or untreated controls, or com-
pared fixed doses of higher-intensity statins with moderate-
intensity statins. These trials were not designed to evaluate the 
effect of titrated (dose-adjusted) statin treatment to achieve 
prespecified LDL-C or non–HDL-C goals.
Therefore, the Expert Panel was unable to find RCT evi-
dence to support titrating cholesterol-lowering drug therapy to 
achieve target LDL-C or non–HDL-C levels, as recommended 
by Adult Treatment Panel III.6–8 Notably, the Expert Panel did 
find RCT evidence that use of therapy (eg, niacin) to addition-
ally lower non–HDL-C, once an LDL-C target was achieved, 
did not further reduce ASCVD outcomes.9 The Expert Panel 
also found extensive RCT evidence that the appropriate inten-
sity of statin therapy should be used to reduce ASCVD risk 
in those most likely to benefit. The work of the Expert Panel 
was informed by the reports of the Lifestyle Management10 
and Risk Assessment Work Groups11 (Figure 1). A summary 
of the major recommendations for the treatment of cholesterol 
to reduce ASCVD risk are provided in Table 3.
2.1. Lifestyle as the Foundation for ASCVD Risk-
Reduction Efforts
It must be emphasized that lifestyle modification (ie, adher-
ing to a heart-healthy diet, regular exercise habits, avoid-
ance of tobacco products, and maintenance of a healthy 
weight) remains a crucial component of health promotion 
Table 2. What’s New in the Guideline?*
1 Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups
1. This guideline is based on a comprehensive set of data from  
RCTs from which 4 statin benefit groups were identified that 
focus efforts to reduce ASCVD events in secondary and primary 
prevention.
2. This guideline identifies high-intensity and moderate-intensity  
statin therapy for use in secondary and primary prevention.
2 A New Perspective on LDL-C and/or Non–HDL-C Treatment Goals
1. The Expert Panel was unable to find RCT evidence to support  
 continued use of specific LDL-C or non–HDL-C treatment 
targets.
2. The appropriate intensity of statin therapy should be used to  
reduce ASCVD risk in those most likely to benefit.
3. Nonstatin therapies, as compared with statin therapy, do not  
 provide acceptable ASCVD risk-reduction benefits relative  
to their potential for adverse effects in the routine prevention  
of ASCVD.
3 Global Risk Assessment for Primary Prevention
1. This guideline recommends use of the new Pooled Cohort  
 Equations to estimate 10-year ASCVD risk in both white and  
black men and women.
2. By more accurately identifying higher-risk individuals for statin  
 therapy, the guideline focuses statin therapy on those most  
likely to benefit.
3. It also indicates, on the basis of RCT data, those high-risk  
groups that might not benefit.
4. This guideline recommends a discussion between clinicians  
and patients before initiation of statin therapy.
4 Safety Recommendations
1. This guideline used RCTs to identify important safety  
 considerations in individuals receiving treatment of blood 
cholesterol to reduce ASCVD risk.
2. Using RCTs to determine statin adverse effects facilitates  
 understanding of the net benefit from statin therapy.
3. This guideline provides expert guidance on management of  
statin-associated adverse effects, including muscle symptoms.
5 Role of Biomarkers and Noninvasive Tests
1. Treatment decisions in selected individuals who are not included  
 in the 4 statin benefit groups may be informed by other factors  
as recommended by the Risk Assessment Work Group and  
Blood Cholesterol Expert Panel.
6 Future Updates to the Blood Cholesterol Guideline
1. This is a comprehensive guideline for the evidence-based  
treatment of blood cholesterol to reduce ASCVD risk.
2. Future updates will build on this foundation to provide expert  
 guidance on the management of complex lipid disorders and 
incorporate refinements in risk stratification based on critical 
review of emerging data.
3. RCTs comparing alternative treatment strategies are needed in  
 order to inform future evidence-based guidelines for the  
optimum ASCVD risk-reduction approach.
*See Appendix 5, for an expanded discussion of what’s new in the guideline.
ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCT, 
randomized controlled trial.
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and ASCVD risk reduction, both prior to and in concert 
with the use of cholesterol-lowering drug therapies. Healthy 
diet or lifestyle modifications were recommended as back-
ground therapy for the RCTs of cholesterol-lowering drug 
therapy. See the “2013 AHA/ACC Guideline on Lifestyle 
Management to Reduce Cardiovascular Risk”10 for life-
style recommendations for healthy adults. Drug therapy for 
lifestyle-related risk factors such as hypertension is often 
needed and smoking should be avoided.
2.2. Initiation of Statin Therapy
The Expert Panel found extensive and consistent evidence 
supporting the use of statins for the prevention of ASCVD in 
many higher-risk primary- and all secondary-prevention indi-
viduals without New York Heart Association class II–IV heart 
failure who were not receiving hemodialysis. In the RCTs 
reviewed, initiation of moderate-intensity therapy (lowering 
LDL-C by approximately 30% to <50%) or high-intensity 
statin therapy (lowering LDL-C by approximately ≥50%) 
is a critical factor in reducing ASCVD events. Moreover, 
statin therapy reduces ASCVD events across the spectrum 
of baseline LDL-C levels ≥70 mg/dL. In addition, the rela-
tive reduction in ASCVD risk is consistent for primary and 
secondary prevention and for various patient subgroups. Of 
note, the absolute reduction in ASCVD events is proportional 
to baseline absolute ASCVD risk. Therefore, statin therapy 
is recommended for individuals at increased ASCVD risk 
who are most likely to experience a net benefit in terms of 
the potential for ASCVD risk reduction and the potential for 
adverse effects (Table 3; Figure 2).
On the basis of this large and consistent body of evidence, 
4 major statin benefit groups were identified for whom the 
ASCVD risk reduction clearly outweighs the risk of adverse 
events based on a strong body of evidence. These are 1) sec-
ondary prevention in individuals with clinical ASCVD, 2) 
primary prevention in individuals with primary elevations 
of LDL-C ≥190 mg/dL, 3) primary prevention in individuals 
with diabetes 40 to 75 years of age who have LDL-C 70 to 189 
mg/dL, and 4) primary prevention in individual without dia-
betes and with estimated 10-year ASCVD risk ≥7.5%, 40 to 
75 years of age who have LDL-C 70 to 189 mg/dL. Moderate 
evidence supports the use of statins for primary prevention 
in individuals with 5% to <7.5% 10-year ASCVD risk, 40 to 
75 years of age with LDL-C 70 to 189 mg/dL. Selected indi-
viduals with <5% 10-year ASCVD risk, or <40 or >75 years 
of age may also benefit from statin therapy. Clinicians and 
patients should engage in a discussion of the potential for 
ASCVD risk-reduction benefits, adverse effects, drug–drug 
interactions, and consider patient preferences for treatment. 
This discussion also provides the opportunity to re-emphasize 
healthy-lifestyle habits and address other risk factors.
Clinical ASCVD is defined by the inclusion criteria for 
the secondary-prevention statin RCTs (acute coronary syn-
dromes, a history of MI, stable or unstable angina, coronary 
or other arterial revascularization, stroke, transient ischemic 
attack, or peripheral arterial disease presumed to be of ath-
erosclerotic origin). For primary prevention in individuals 
without clinical ASCVD or diabetes who have an LDL-C 
70 to 189 mg/dL, the estimated absolute 10-year risk of 
ASCVD (defined as nonfatal MI, CHD death, or nonfatal and 
fatal stroke) should be used to guide the initiation of statin 
therapy. The 10-year ASCVD risk should be estimated with 
the Pooled Cohort Equations (Section 4.7). For the primary 
prevention of ASCVD in individuals with diabetes (diabe-
tes mellitus type 1 and type 2), estimated 10-year ASCVD 
risk can also be used to guide the intensity of statin therapy. 
For those with clinical ASCVD or with LDL-C ≥190 mg/dL 
who are already in a statin benefit group, it is not appropri-
ate to estimate 10-year ASCVD risk. In primary preven-
tion, additional factors may influence ASCVD risk in those 
for whom a risk-based decision is unclear. These include a 
primary LDL-C ≥160 mg/dL or other evidence of genetic 
hyperlipidemias, family history of premature ASCVD with 
onset <55 years of age in a first-degree male relative or <65 
years of age in a first-degree female relative, high-sensitivity 
C-reactive protein ≥2 mg/L, coronary artery calcium score 
Figure 1. Overview of the Expert Panel’s Guideline. RCTs indicates randomized controlled trials.
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Table 3. Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults (See Tables 4, 
8, 9, and 10 for the complete recommendations; and Table 5 for definition of statin intensity)
Recommendations ACC/AHA COR ACC/AHA LOE
A. Heart-healthy lifestyle habits should be encouraged for all individuals
B. The appropriate intensity of statin therapy should be initiated or continued:
1. Clinical ASCVD*
a. Age ≤75 y and no safety concerns: High-intensity statin I A
b. Age >75 y or safety concerns: Moderate-intensity statin I A
2. Primary prevention – Primary LDL-C ≥190 mg/dL
a. Rule out secondary causes of hyperlipidemia (Table 6) I B
b. Age ≥21 y: High-intensity statin I B
c. Achieve at least a 50% reduction in LDL-C IIa B
d. LDL-C lowering nonstatin therapy may be considered to further reduce LDL-C IIb C
3. Primary prevention—Diabetes 40–75 years of age and LDL-C 70–189 mg/dL
a. Moderate-intensity statin I A
b. Consider high-intensity statin when ≥7.5% 10-y ASCVD risk using the Pooled Cohort Equations† IIa B
4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
a. Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equations† in those  
NOT receiving a statin; estimate risk every 4–6 y
I B
b. To determine whether to initiate a statin, engage in a clinician-patient discussion of the potential for  
ASCVD risk reduction, adverse effects, drug–drug interactions, and patient preferences 
c. Re-emphasize heart-healthy lifestyle habits and address other risk factors
IIa C
i. ≥7.5% 10-y ASCVD risk: Moderate- or high-intensity statin I A
ii. 5 to <7.5% 10-y ASCVD risk: Consider moderate-intensity statin IIa B
iii. Other factors may be considered‡: LDL-C ≥160 mg/dL, family history of premature ASCVD,  
hs-CRP ≥2.0 mg/L, CAC score ≥300 Agaston units, ABI <0.9, or lifetime ASCVD risk
IIb C
5. Primary prevention when LDL-C <190 mg/dL and age <40 or >75 y, or <5% 10-y ASCVD risk 
a. Statin therapy may be considered in selected individuals‡
IIb C
6.  Statin therapy is not routinely recommended for individuals with NYHA class II-IV heart failure  
or who are receiving maintenance hemodialysis
C.  Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments
1.  Assess adherence, response to therapy, and adverse effects within 4–12 wk following statin initiation or change in therapy I A
a. Measure a fasting lipid panel I A
b. Do not routinely monitor ALT or CK unless symptomatic IIa C
c. Screen and treat type 2 diabetes according to current practice guidelines. Heart-healthy lifestyle habits  
should be encouraged to prevent progression to diabetes
I B
d. Anticipated therapeutic response: approximately ≥50% reduction in LDL-C from baseline for high-intensity  
statin and 30% to <50% for moderate-intensity statin
IIa B
i. Insufficient evidence for LDL-C or non–HDL-C treatment targets from RCTs
ii.  For those with unknown baseline LDL-C, an LDL-C <100 mg/dL was observed in RCTs of  
high-intensity statin therapy
e. Less than anticipated therapeutic response:
i. Reinforce improved adherence to lifestyle and drug therapy I A
ii. Evaluate for secondary causes of hyperlipidemia if indicated (Table 6) I A
iii.  Increase statin intensity, or if on maximally-tolerated statin intensity, consider addition of nonstatin  
therapy in selected high-risk individuals§
IIb C
f.  Regularly monitor adherence to lifestyle and drug therapy every 3–12 mo once adherence has been established.  
Continue assessment of adherence for optimal ASCVD risk reduction and safety
I A
D.  In individuals intolerant of the recommended intensity of statin therapy, use the maximally tolerated intensity of statin. I B
1. If there are muscle or other symptoms, establish that they are related to the statin IIa B
2. For specific recommendations on managing muscle symptoms (Table 8)
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease 
presumed to be of atherosclerotic origin.
†Estimated 10-year or “hard” ASCVD risk includes first occurrence of nonfatal MI, CHD death, and nonfatal and fatal stroke as used by the Risk Assessment Work Group in 
developing the Pooled Cohort Equations (http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/2013-Prevention-Guideline-Tools.aspx).
‡These factors may include primary LDL-C ≥160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years of age in a 
first-degree male relative or <65 years of age in a first-degree female relative; hs-CRP ≥2 mg/L; CAC score ≥300 Agatston units or ≥75th percentile for age, sex, and ethnicity 
(for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment 
could be identified in the future.
§High-risk individuals include those with clinical ASCVD, an untreated LDL-C ≥190 mg/dL suggesting genetic hypercholesterolemia, or individuals with diabetes 40 to 75 years 
of age and LDL-C 70 to 189 mg/dL.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ALT, alanine aminotransferase, a test of hepatic function; 
ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; CK, creatine kinase, a test of muscle injury; COR, Class 
of Recommendation; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LOE, Level of 
Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, New York Heart Association; RCTs, randomized controlled trials; and TIA, transient ischemic attack.
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Figure 2. Summary of Statin Initiation Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults 
(See Figures 3, 4, and 5 for More Detailed Management Information). Colors correspond to the Classes of Recommendation in Table 
1. Assessment of the potential for benefit and risk from statin therapy for ASCVD prevention provides the framework for clinical deci-
sion making incorporating patient preferences. *Percent reduction in LDL-C can be used as an indication of response and adherence to 
therapy, but is not in itself a treatment goal. †The Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals 
with and without diabetes. The estimator within this application should be used to inform decision making in primary prevention patients 
not on a statin. ‡Consider moderate-intensity statin as more appropriate in low-risk individuals. §For those in whom a risk assessment is 
uncertain, consider factors such as primary LDL-C ≥160 mg/dL or other evidence of genetic hyperlipidemias, family history of premature 
ASCVD with onset <55 years of age in a first-degree male relative or <65 years of age in a first-degree female relative, hs-CRP ≥2 mg/L, 
CAC score ≥300 Agatston units, or ≥75th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.
org/CACReference.aspx), ABI <0.9, or lifetime risk of ASCVD. Additional factors that may aid in individual risk assessment may be identi-
fied in the future. ‖Potential ASCVD risk-reduction benefits. The absolute reduction in ASCVD events from moderate- or high-intensity 
statin therapy can be approximated by multiplying the estimated 10-year ASCVD risk by the anticipated relative-risk reduction from the 
intensity of statin initiated (~30% for moderate-intensity statin or ~45% for high-intensity statin therapy). The net ASCVD risk-reduction 
benefit is estimated from the number of potential ASCVD events prevented with a statin, compared to the number of potential excess 
adverse effects. ¶Potential adverse effects. The excess risk of diabetes is the main consideration in ~0.1 excess cases per 100 individu-
als treated with a moderate-intensity statin for 1 year and ~0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 
year. In RCTs, both statin-treated and placebo-treated participants experienced the same rate of muscle symptoms. The actual rate of 
statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapy should be evaluated 
(see Table 8, Safety Recommendation 8). ABI indicates ankle-brachial index; ASCVD, atherosclerotic cardiovascular disease; CAC, coro-
nary artery calcium; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; and 
RCT, randomized controlled trial.
Yes
Age ≤75 y
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)Age ≥21 y and a candidate 
for statin therapy
Yes
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Yes
No
Moderate-intensity statin
No
Primary prevention 
(No diabetes, LDL-C 70 to 189 mg/dL, and not receiving statin therapy)
Estimate 10-y ASCVD risk every 4-6 y
using Pooled Cohort Equations†
No
In selected individuals, additional 
factors may be considered to inform 
treatment decision making§
Heart-healthy lifestyle habits are the foundation of ASCVD prevention
(See 2013 AHA/ACC Lifestyle Management Guideline)
Yes
Estimated 10-y ASCVD risk ≥7.5%†
High-intensity statin
Age >75 y OR if not candidate for 
high-intensity statin
Moderate-intensity statin
Yes
Yes
Clinical 
ASCVD
LDL-C ≥190 
mg/dL
Diabetes
LDL-C 70-189 mg/dL
Age 40-75 y
Definitions of High- and Moderate-
Intensity Statin Therapy*
(See Table 5)
High
Daily dose lowers 
LDL-C by approx. 
≥50%
Moderate
Daily dose lowers 
LDL-C by approx. 
30% to <50%
≥7.5%
10-y ASCVD risk
(Moderate- or high-
intensity statin)
5% to <7.5%
10-y ASCVD risk
(Moderate-intensity 
statin)
<5%
10-y ASCVD 
risk‡
Age <40 or >75 y 
and LDL-C <190 
mg/dL‡
Clinician-Patient Discussion
Prior to initiating statin therapy, discuss:
    1. Potential for ASCVD risk-reduction benefits║
    2. Potential for adverse effects and drug–drug interactions¶
    3. Heart-healthy lifestyle
    4. Management of other risk factors
    5. Patient preferences
    6. If decision is unclear, consider primary LDL-C ≥160 mg/dL, family history of premature 
        ASCVD, lifetime ASCVD risk, abnormal CAC score or ABI, or hs-CRP ≥2 mg/L§
No to statin
Yes to statin
 Encourage adherence to lifestyle 
 Initiate statin at appropriate intensity
 Manage other risk factors
 Monitor adherence* (See Fig 5)
 Emphasize adherence to lifestyle 
 Manage other risk factors
 Monitor adherence
DM age <40 
or >75 y or 
LDL-C <70 
mg/dL
Regularly monitor adherence to 
lifestyle and drug therapy with 
lipid and safety assessments 
(See Fig 5)
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≥300 Agatston units or ≥75th percentile for age, sex, and 
ethnicity (for additional information, see http://www.mesa-
nhlbi.org/CACReference.aspx.), ankle-brachial index <0.9, 
and elevated lifetime risk of ASCVD.
The findings support the use of statins to prevent both non-
fatal and fatal ASCVD events. Such an approach can reduce 
the large burden of disability from nonfatal stroke (for which 
women are at higher risk than men) and nonfatal CHD events. 
Primary and secondary prevention of ASCVD with statins can 
positively impact rising healthcare costs. In addition, a high 
level of evidence was found that statins reduce total mortal-
ity in individuals with a history of prior ASCVD events (eg, 
secondary-prevention settings). In individuals with no prior 
history of ASCVD events (eg, primary-prevention settings), 
there is moderate evidence that statins reduce total mortality 
in individuals at increased ASCVD risk. It should be noted 
that 2 meta-analyses published after the completion of the 
Expert Panel’s systematic review provide strong evidence that 
statins reduce total mortality in primary prevention.12,13
3. Critical Questions and Conclusions
3.1. Identification of CQs
Although limited to 3 CQs, these questions were considered 
the most important to answer in order to identify whom to treat 
and with what treatment(s) and to consider how intensively 
the treatments should be used. The first 2 CQs evaluated the 
evidence for LDL-C and non–HDL-C goals for the secondary 
and primary prevention of ASCVD with cholesterol-lowering 
drug therapy. Titration to specific LDL-C goals has been con-
sidered a fundamental therapeutic strategy in deciding on 
the adequacy of cholesterol-lowering therapy for secondary 
and primary prevention. Therefore, a comprehensive system-
atic review of the evidence base supporting this concept was 
essential. The third CQ had several objectives:
•	 Identify groups of patients who will benefit from phar-
macological treatment,
•	 Define the pharmacological treatment(s) for which there 
is the best evidence of net benefit, and
•	 Provide guidance on the appropriate intensity of phar-
macological treatment to reduce ASCVD risk.
3.1.1. CQ1: LDL-C and Non–HDL-C Goals in Secondary 
Prevention
CQ1: What is the evidence for LDL-C and non–HDL-C 
goals for the secondary prevention of ASCVD?
The Expert Panel reviewed 19 RCTs to answer CQ1. Although 
CQ1 is supported conceptually by an extrapolation of observa-
tional studies and observational data from RCTs, no data were 
identified for treatment or titration to a specific LDL-C goal in 
adults with clinical ASCVD. The majority of studies confirm-
ing the efficacy of cholesterol reduction in improving clinical 
outcomes in patients with clinical ASCVD used a single fixed-
dose statin to lower LDL-C levels. In the 4S trial, 37% had the 
dose of simvastatin raised from 20 mg/d to 40 mg/d to achieve 
a total cholesterol level <200 mg/dL.16 The Expert Panel was 
unable to find any RCTs that evaluated titration of all individu-
als in a treatment group to specific LDL-C targets <100 mg/dL 
or <70 mg/dL, nor were any RCTs comparing 2 LDL-C treat-
ment targets identified. No statin RCTs reporting on-treatment 
non–HDL-C levels were identified. (In CQ3, statin-nonstatin 
combination therapy was evaluated.)
3.1.2. CQ2: LDL-C and Non–HDL-C Goals in Primary 
Prevention
CQ2: What is the evidence for LDL-C and non–HDL-C 
goals for the primary prevention of ASCVD?
The Expert Panel reviewed 6 RCTs. The 4 studies confirming 
the efficacy of cholesterol reduction in improving clinical out-
comes in patients without ASCVD used fixed-dose statin ther-
apy to lower LDL-C levels. In the AFCAPS-TEXCAPS (Air 
Force/Texas Coronary Atherosclerosis Prevention Study) trial,17 
in 50% of participants, the lovastatin dose was raised from 20 
mg to 40 mg to achieve an LDL-C level <110 mg/dL. In the 
MEGA (Management of Elevated Cholesterol in the Primary 
Prevention Group of Adult Japanese) trial,18 the dose of pravas-
tatin could be uptitrated from 10 mg to 20 mg to achieve a total 
cholesterol level <220 mg/dL. The Expert Panel did not find any 
RCTs that evaluated titration of all individuals in a treatment 
group to specific LDL-C targets <100 mg/dL or <70 mg/dL, 
nor were any RCTs comparing 2 LDL-C treatment targets iden-
tified. No trials reported on-treatment non–HDL-C levels.
3.1.3. CQ3: Efficacy and Safety of Cholesterol-Lowering 
Medications
CQ3: For primary and secondary prevention, what is the 
impact on lipid levels, effectiveness, and safety of specific 
cholesterol-modifying drugs used for lipid management in 
general and in selected subgroups?
The populations examined included primary-prevention adult 
patients who could not have a diagnosis of CHD or cardio-
vascular disease. Interventions included pharmacotherapy with 
single-drug therapies or combination-drug therapies with any 
drug therapy used for treating blood cholesterol, including 
statins, fibrates (fenofibrate, gemfibrozil), nicotinic acid (nia-
cin in immediate-, slow-, or extended-release form), bile acid 
sequestrants, ezetimibe, omega-3 fatty acids (also called marine 
fatty acids, including eicosapentaenoic acid alone, docosahex-
anoic acid alone, eicosapentaenoic acid plus docosahexanoic 
acid, and alpha-linolenic acid). There were no ASCVD out-
comes identified for plant sterols, sterol esters, stanols, or sta-
nol esters. A single ASCVD outcomes trial19 used Xuezhikang, 
an extract from red yeast Chinese rice, which was not available 
in the United States during the timeframe for evidence review, 
so no recommendations were made regarding its use.
The recommendations synthesize the evidence retrieved 
for answering CQ3, along with the evidence from the trials 
included in CQ1 and CQ2, to guide the use of cholesterol-low-
ering drugs for secondary or primary prevention of ASCVD.
4. Statin Treatment: Recommendations
For each recommendation, the grades of the recommendation 
by both the NHLBI and ACC/AHA methods are provided. 
Major treatment recommendations are listed in Table 4, and 
statin intensities are defined in Table 5. The safety (statin and 
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Table 4. Recommendations for Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults—Statin 
Treatment (High, Moderate, and Low Statin Intensities are Defined in Table 5)
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
Treatment Targets
1. The Expert Panel makes no recommendations for or against specific  
 LDL-C or non–HDL-C targets for the primary or secondary  
prevention of ASCVD.
N  
(No recommendation)
1–4 — —
Secondary Prevention
1. High-intensity statin therapy should be initiated or continued  
 as first-line therapy in women and men ≤75 years of age  
who have clinical ASCVD*, unless contraindicated.
A (Strong) 1,6–8,10–23,26–28 I A
2. In individuals with clinical ASCVD* in whom high-intensity  
 statin therapy would otherwise be used, when high-intensity  
statin therapy is contraindicated† or when characteristics  
predisposing to statin-associated adverse effects are present,  
moderate-intensity statin should be used as the second option  
if tolerated (Table 8 for Safety of Statins, Recommendation 1).
A (Strong) 13–22,24,27,28 I A
3. In individuals with clinical ASCVD >75 years of age, it is reasonable  
 to evaluate the potential for ASCVD risk-reduction benefits and for  
adverse effects and drug–drug interactions and to consider patient  
preferences when initiating a moderate- or high-intensity statin.  
It is reasonable to continue statin therapy in those who are tolerating it.
E (Expert Opinion) — IIa B16,20–43
Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/dL
1. Individuals with LDL-C ≥190 mg/dL or triglycerides ≥500 mg/dL should  
be evaluated for secondary causes of hyperlipidemia (Table 6).
B (Moderate) 75 I‡ B44,45
2. Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated  
with statin therapy (10-year ASCVD risk estimation is not required):
•	Use high-intensity statin therapy unless contraindicated.
•	For individuals unable to tolerate high-intensity statin therapy,  
use the maximum tolerated statin intensity.
B (Moderate) 6,19,28,33–35, 
37,38
I§ B
3. For individuals ≥21 years of age with an untreated primary  
 LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy  
to achieve at least a 50% LDL-C reduction.
E (Expert Opinion) — IIa B20,46–50
4. For individuals ≥21 years of age with an untreated primary  
 LDL-C ≥190 mg/dL, after the maximum intensity of statin  
therapy has been achieved, addition of a nonstatin drug may  
be considered to further lower LDL-C. Evaluate the potential  
for ASCVD risk-reduction benefits, adverse effects, and  
drug–drug interactions, and consider patient preferences.
E (Expert Opinion) — IIb C51
Prevention in Individuals With Diabetes and LDL-C 70–189 mg/dL
1. Moderate-intensity statin therapy should be initiated or continued for  
adults 40–75 years of age with diabetes.
A (Strong) 19,29–34,40 I A
2. High-intensity statin therapy is reasonable for adults 40–75 years of age with  
diabetes with a ≥7.5% estimated 10-year ASCVD risk‖ unless contraindicated.
E (Expert Opinion) — IIa B49,52
3. In adults with diabetes, who are <40 years of age or >75 years of age, or with  
 LDL <70 mg/dL it is reasonable to evaluate the potential for ASCVD benefits  
and for adverse effects and drug–drug interactions and to consider patient  
preferences when deciding to initiate, continue, or intensify statin therapy.
E (Expert Opinion) — IIa C53–62
Primary Prevention in Individuals Without Diabetes and With LDL-C 70–189 mg/dL
1. The Pooled Cohort Equations should be used to estimate 10-year ASCVD‖ risk  
 for individuals with LDL-C 70–189 mg/dL without clinical ASCVD* to guide  
initiation of statin therapy for the primary prevention of ASCVD.
E (Expert Opinion) — I B11
2. Adults 40–75 years of age with LDL-C 70–189 mg/dL, without clinical ASCVD*  
 or diabetes, and with an estimated 10-year ASCVD‖ risk ≥7.5% should be  
treated with moderate- to high-intensity statin therapy.
A (Strong) 28,34–36,38,42–44, 
47,49–56,76
I A
3. It is reasonable to offer treatment with a moderate-intensity statin to adults  
 40–75 years of age, with LDL-C 70–189 mg/dL, without clinical ASCVD* or  
diabetes, and with an estimated 10-year ASCVD‖ risk of 5% to <7.5%.
C (Weak) 28,34–36,38,42–44, 
47,49–56,76
IIa B
(Continued)
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nonstatin) recommendations are in Section 5. A complete list-
ing of the evidence statements supporting each recommenda-
tion, along with the references, is provided in Appendix 4.
4.1. Intensity of Statin Therapy in Primary and 
Secondary Prevention
The Expert Panel defines the intensity of statin therapy on 
the basis of the average expected LDL-C response to a spe-
cific statin and dose. “High-intensity,” “moderate-intensity,” 
and “low-intensity” statin therapy definitions were derived 
from the systematic reviews for CQ1 and CQ2. The basis for 
differentiation among specific statins and doses arose from 
the RCTs included in CQ1, where there was a high level of 
evidence that high-intensity statin therapy with atorvastatin 
40 mg to 80 mg reduced ASCVD risk more than moderate-
intensity statin therapy with atorvastatin 10 mg, pravastatin 
40 mg, or simvastatin 20 mg to 40 mg twice daily. Classifying 
specific statins and doses by the percent reduction in LDL-C 
level is based on evidence that the relative reduction in 
ASCVD risk from statin therapy is related to the degree by 
which LDL-C is lowered. However, no variation in the rela-
tive reduction in ASCVD risk was observed after the data 
were adjusted for LDL-C reduction. Furthermore, there is 
no differentiation between the specific statins and doses used 
in primary- and secondary-prevention RCTs, according to a 
high level of evidence that statins reduce ASCVD risk simi-
larly in both populations.
Percent reductions in LDL-C for a specific statin and dose 
were calculated for the RCTs included in individual meta-anal-
yses conducted by the Cholesterol Treatment Trialists (CTT) 
in 2010,20 in which statin therapy reduced ASCVD events. 
High-intensity statin therapy on average lowers LDL-C by 
approximately ≥50%, moderate-intensity statin therapy low-
ers LDL-C by approximately 30% to <50%, and lower-inten-
sity statin therapy lowers LDL-C by <30% (Table 5).
4.2. LDL-C and Non–HDL-C Treatment Goals
The Expert Panel did not find evidence to support titrating 
cholesterol-lowering drug therapy to achieve optimal LDL-C 
or non–HDL-C levels because the clinical trials were essen-
tially fixed-dose trials (CQ1 and CQ2). Dosage increases did 
occur in a few RCTs with the intent of maximizing statin 
therapy. Therefore, these were not truly tests of defining 
optimal goals for LDL-C in primary and secondary preven-
tion because not all individuals in the statin treatment groups 
received drug therapy titrated to achieve a specific LDL-C or 
Table 4. Continued
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
4. Before initiation of statin therapy for the primary prevention of ASCVD in  
 adults with LDL-C 70–189 mg/dL without clinical ASCVD* or diabetes, it is  
reasonable for clinicians and patients to engage in a discussion that considers 
the potential for ASCVD risk-reduction benefits and for adverse effects and 
drug–drug interactions, as well as patient preferences for treatment.
E (Expert Opinion) — IIa C63
5. In adults with LDL-C <190 mg/dL who are not otherwise identified in a  
 statin benefit group, or for whom after quantitative risk assessment a  
risk-based treatment decision is uncertain, additional factors¶ may be 
considered to inform treatment decision making. In these individuals, statin 
therapy for primary prevention may be considered after evaluation of the 
potential for ASCVD risk-reduction benefits, adverse effects, and drug–drug 
interactions and consider patient preferences.
E (Expert Opinion) — IIb C11,13
Heart Failure and Hemodialysis
1. The Expert Panel makes no recommendations regarding the initiation or  
 discontinuation of statins in patients with NYHA class II–IV ischemic systolic 
heart failure or in patients on maintenance hemodialysis.
N  
(No Recommendation)
71,72 — —
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral 
arterial disease presumed to be of atherosclerotic origin.
†Contraindications, warnings, and precautions are defined for each statin according to the manufacturer’s prescribing information.64–70
‡Individuals with secondary causes of hyperlipidemia were excluded from RCTs reviewed. A triglyceride level ≥500 mg/dL was an exclusion criterion for almost all 
RCTs. Therefore, ruling out secondary causes is necessary to avoid inappropriate statin therapy.
§No RCTs included only individuals with LDL-C ≥190 mg/dL. However, many trials did include individuals with LDL-C ≥190 mg/dL, and all of these trials consistently 
demonstrated a reduction in ASCVD events. In addition, the Cholesterol Treatment Trialists meta-analyses have shown that each 39-mg/dL reduction in LDL-C with 
statin therapy reduced ASCVD events by 22%, and the relative reductions in ASCVD events were consistent across the range of LDL-C levels. Therefore, individuals with 
primary LDL-C ≥190 mg/dL should be treated with statin therapy.
‖Estimated 10-year or “hard” ASCVD risk includes first occurrence of nonfatal MI, coronary heart disease death, and nonfatal and fatal stroke as used by the Risk 
Assessment Work Group in developing the Pooled Cohort Equations.
¶These factors may include primary LDL-C ≥160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years of age 
in a first-degree male relative or <65 years of age in a first-degree female relative; high-sensitivity C-reactive protein ≥2 mg/L; CAC score ≥300 Agatston units or ≥75th 
percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional 
factors that might aid in individual risk assessment could be identified in the future.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary 
artery calcium; COR, Class of Recommendation; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, 
National Heart, Lung, and Blood Institute; NYHA, New York Heart Association; RCTs, randomized controlled trials; TIA, transient ischemic attack; and —, not applicable.
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non–HDL-C goal, nor were specific treatment targets com-
pared. One RCT in CQ3 was identified that showed no addi-
tional ASCVD event reduction from the addition of nonstatin 
therapy to further lower non–HDL-C levels once an LDL-C 
goal had been reached. In AIM-HIGH (Atherothrombosis 
Intervention in Metabolic Syndrome With Low HDL/High 
Triglycerides and Impact on Global Health Outcomes), the 
additional reduction in non–HDL-C levels (as well as further 
reductions in apolipoprotein B, lipoprotein[a], and triglyc-
erides in addition to HDL-C increases) with niacin therapy 
did not further reduce ASCVD risk in individuals treated to 
LDL-C levels of 40 to 80 mg/dL.9
Therefore, given the absence of data on titration of drug 
therapy to specific goals, no recommendations are made for or 
against specific LDL-C or non–HDL-C goals for the primary 
or secondary prevention of ASCVD.
4.3. Secondary Prevention
Women and men with clinical ASCVD (defined from the 
RCT inclusion criteria as acute coronary syndromes; history 
of MI, stable or unstable angina, coronary or other arterial 
revascularization, stroke, transient ischemic attack, or periph-
eral arterial disease presumed to be of atherosclerotic origin) 
arterial revascularization, stroke, transient ischemic attack, or 
peripheral arterial disease presumed to be of atherosclerotic 
origin are at increased risk for recurrent ASCVD and ASCVD 
death. An extensive body of evidence demonstrates that high-
intensity statin therapy reduces ASCVD events more than 
moderate-intensity statin therapy (Table 4) in individuals with 
clinical ASCVD.
High-intensity statin therapy should be initiated for adults 
≤75 years of age with clinical ASCVD who are not receiving 
statin therapy, or the intensity should be increased in those 
receiving a low- or moderate-intensity statin, unless they have 
a history of intolerance to high-intensity statin therapy or 
other characteristics that could influence safety (Section 5). 
This is consistent with RCT data. In 2 trials, patients were 
previously treated with a moderately intensive statin,46,47 and 
in 2 trials, 75% to 97% of patients had not received prior statin 
therapy.48,78 The high-intensity statins atorvastatin 80 mg and 
rosuvastatin 20 mg daily reduce LDL-C ≥50% on average and 
have been shown to reduce ASCVD events in RCTs.
Although atorvastatin 40 mg reduces LDL-C by approxi-
mately ≥50%, this dose was used in only 1 RCT if the 
participant was unable to tolerate atorvastatin 80 mg/dL. 
Whether an individual receiving atorvastatin 40 mg should 
be uptitrated to atorvastatin 80 mg should be based on the 
potential for an ASCVD risk-reduction benefit and the 
potential for adverse effects, drug–drug interactions, and 
consider patient preferences.
In individuals with clinical ASCVD in whom high-intensity 
statin therapy would otherwise be used, either when high-
intensity statin therapy is contraindicated or when charac-
teristics predisposing to statin-associated adverse effects are 
present, moderate-intensity statin should be used as the second 
option, if tolerated (Section 5). In the relatively few individuals 
>75 years of age who were included in RCTs of high- versus 
moderate-intensity statin therapy, there was no clear evidence 
of an additional reduction in ASCVD events from high-inten-
sity statin therapy. In contrast, individuals >75 years of age 
did experience a reduction in ASCVD events in the trials of 
mostly moderate-intensity statin therapy, as compared with 
control. Therefore, moderate-intensity statin therapy should 
be considered for individuals >75 years of age with clinical 
ASCVD. However, in acknowledgment that older participants 
in RCTs were likely to be healthier than many older individu-
als in the general population, the use of statin therapy should 
be individualized in persons >75 years of age with clinical 
ASCVD, according to the potential for ASCVD risk-reduction 
benefits, adverse effects, drug–drug interactions, and consider 
patient preferences. The Expert Panel considers it reasonable 
to continue statin therapy in persons >75 years of age who 
have clinical ASCVD and are tolerating statin therapy.
The flow diagram for the initiation and management of 
statin therapy in individuals with clinical ASCVD is provided 
in Figure 3.
Table 5. High-, Moderate-, and Low-Intensity Statin Therapy (Used in the RCTs Reviewed by the Expert Panel)*
High-Intensity Statin Therapy Moderate-Intensity Statin Therapy Low-Intensity Statin Therapy
Daily dose lowers LDL-C, on average,  
by approximately ≥50%
Daily dose lowers LDL-C, on average,  
by approximately 30% to <50%
Daily dose lowers LDL-C,  
on average, by <30%
Atorvastatin (40†)–80 mg
Rosuvastatin 20 (40) mg
Atorvastatin 10 (20 ) mg
Rosuvastatin (5 ) 10 mg
Simvastatin 20–40 mg‡
Pravastatin 40 (80 ) mg
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg BID
Pitavastatin 2–4 mg
Simvastatin 10 mg
Pravastatin 10–20 mg
Lovastatin 20 mg
Fluvastatin 20–40 mg
Pitavastatin 1 mg
Boldface type indicates specific statins and doses that were evaluated in RCTs16–18,46–49,64–75,77 included in CQ1, CQ2, and the Cholesterol Treatment Trialists 2010 
meta-analysis included in CQ3.20 All of these RCTs demonstrated a reduction in major cardiovascular events. Italic type indicates statins and doses that have been 
approved by the FDA but were not tested in the RCTs reviewed.
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biological basis for a less-than-average 
response.
†Evidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study.47
‡Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased 
risk of myopathy, including rhabdomyolysis.
BID indicates twice daily; CQ, critical question; FDA, Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized controlled trials.
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4.4. Primary Prevention in Individuals ≥21 Years of 
Age With LDL-C ≥190 mg/dL
This guideline recognizes that individuals ≥21 years of age with 
primary, severe elevations of LDL-C (≥190 mg/dL) have a high 
lifetime risk for ASCVD events. This is due to their lifetime expo-
sure to markedly elevated LDL-C levels arising from genetic 
causes. Thus, at age 21, these individuals should receive statin 
therapy if they have not already been diagnosed and treated before 
this age. Although in most clinical trials individuals with LDL-C 
≥190 mg/dL were not included because of their need for treat-
ment, extensive evidence shows that each 39-mg/dL reduction 
in LDL-C by statin therapy reduces ASCVD risk by about 20%. 
Patients with primary elevations of LDL-C ≥190 mg/dL require 
even more substantial reductions in their LDL-C levels and inten-
sive management of other risk factors to reduce their ASCVD 
event rates. Therefore, it is reasonable to use high-intensity statin 
therapy to achieve at least a 50% reduction. It is recognized that 
maximal statin therapy might not be adequate to lower LDL-C 
sufficiently to reduce ASCVD event risk in individuals with pri-
mary severe elevations of LDL-C. In addition to a maximally tol-
erated dose of statin, nonstatin cholesterol-lowering medications 
are often needed to lower LDL-C to acceptable levels in these 
individuals. Because the hypercholesterolemia in these high-risk 
individuals is often genetically determined, family screening is 
especially important in this group to identify additional family 
members who would benefit from assessment and early treatment.
Secondary causes of severe elevations of LDL-C ≥190 mg/dL 
and triglycerides ≥500 mg/dL often contribute to the magni-
tude of the hyperlipidemia and should be evaluated and treated 
appropriately. For guidance, we note that in a lipid specialty 
clinic, the most frequently encountered secondary conditions 
were excessive alcohol intake, uncontrolled diabetes, and 
overt albuminuria.79 Table 6 focuses on secondary causes of 
hyperlipidemia most likely encountered in clinical practice.80 
Management of individuals with fasting triglycerides ≥500 
mg/dL has been addressed in an AHA statement.45
Figure 3. Initiating Statin Therapy in Individuals With Clinical ASCVD. Colors correspond to the Classes of Recommendation in Table 1. *Fasting 
lipid panel preferred. In a nonfasting individual, a non–HDL-C level ≥220 mg/dL could indicate genetic hypercholesterolemia that requires further 
evaluation or a secondary etiology. If nonfasting triglycerides are ≥500 mg/dL, a fasting lipid panel is required. †It is reasonable to evaluate the 
potential for ASCVD benefits and for adverse effects, and to consider patient preferences, in initiating or continuing a moderate- or high-intensity 
statin in individuals with ASCVD who are >75 years of age. ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; 
CK, creatine kinase; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; and ULN, upper limit of normal.
Table 6. Secondary Causes of Hyperlipidemia Most Commonly 
Encountered in Clinical Practice
Secondary Cause Elevated LDL-C Elevated Triglycerides
Diet Saturated or trans fats, 
weight gain, anorexia 
nervosa
Weight gain, very-low-fat 
diets, high intake of refined 
carbohydrates, excessive 
alcohol intake
Drugs Diuretics, cyclosporine, 
glucocorticoids, 
amiodarone
Oral estrogens, 
glucocorticoids, bile acid 
sequestrants, protease 
inhibitors, retinoic 
acid, anabolic steroids, 
sirolimus, raloxifene, 
tamoxifen, beta blockers 
(not carvedilol), thiazides
Diseases Biliary obstruction,  
nephrotic syndrome
Nephrotic syndrome, 
chronic renal failure, 
lipodystrophies
Disorders and  
altered states  
of metabolism
Hypothyroidism,  
obesity, pregnancy*
Diabetes (poorly controlled), 
hypothyroidism, obesity; 
pregnancy*
*Cholesterol and triglycerides rise progressively throughout pregnancy;80 
treatment with statins, niacin, and ezetimibe are contraindicated during pregnancy 
and lactation.
LDL-C indicates low-density lipoprotein cholesterol.
Adapted with permission from Stone et al.80
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Figure 4. Initiating Statin Therapy in Individuals Without Clinical ASCVD. Colors correspond to the Classes of Recommendation in 
Table 1. *Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level ≥220 mg/dL could indicate genetic hypercho-
lesterolemia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are ≥500 mg/dL, a fasting lipid panel 
is required. †The Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals with and without diabetes. 
A downloadable spreadsheet enabling estimation of 10-year and lifetime risk for ASCVD and a Web-based calculator are available 
at http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-
Quality-Standards/2013-Prevention-Guideline-Tools.aspx. ‡For those in whom a risk assessment is uncertain, consider factors such 
as primary LDL-C ≥160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years 
of age in a first-degree male relative or <65 years of age in a first-degree female relative, high-sensitivity C-reactive protein ≥2 mg/L; 
CAC ≥300 Agatston units or ≥75th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/
CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that may aid in individual risk assessment could be 
identified in the future. §1) Potential ASCVD risk-reduction benefits. The absolute reduction in ASCVD events from moderate- or 
high-intensity statin therapy can be approximated by multiplying the estimated 10-year ASCVD risk by the anticipated relative-risk 
reduction from the intensity of statin initiated (~30% for moderate-intensity statin or ~45% for high-intensity statin therapy). The net 
ASCVD risk-reduction benefit is estimated from the number of potential ASCVD events prevented with a statin, compared to the 
number of potential excess adverse effects. 2) Potential adverse effects. The excess risk of diabetes is the main consideration in 
~0.1 excess cases per 100 individuals treated with a moderate-intensity statin for 1 year and ~0.3 excess cases per 100 individuals 
treated with a high-intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants experienced the same 
rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms 
attributed to statin therapy should be evaluated (see Table 8, Safety Recommendation 8). ABI indicates ankle-brachial index; ALT, 
alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CK, creatine kinase; FH, familial 
hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; RCT, randomized controlled trial; and 
ULN, upper limit of normal.
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The flow diagram for the initiation and management of 
statin therapy in individuals with LDL-C ≥190 mg/dL is pro-
vided in Figure 4.
4.5. Primary Prevention in Individuals With 
Diabetes
A high level of evidence supports the use of moderate-intensity 
statin therapy in persons with diabetes who are 40 to 75 years 
of age. The only trial of high-intensity statin therapy in primary 
prevention was performed in a population without diabetes. 
However, a high level of evidence existed for event reduc-
tion with statin therapy in individuals with a ≥7.5% estimated 
10-year ASCVD risk (Section 4.6) who did not have diabetes to 
recommend high-intensity statin therapy preferentially for indi-
viduals with diabetes and a ≥7.5% estimated 10-year ASCVD 
risk (Section 4.7). This consideration for those with diabetes 
who are 40 to 75 years of age recognizes that these individuals 
are at substantially increased lifetime risk for ASCVD events 
and death. Moreover, individuals with diabetes experience 
greater morbidity and worse survival after the onset of clinical 
ASCVD. In persons with diabetes who are <40 years of age or 
>75 years of age, or whose LDL-C is <70 mg/dL, statin ther-
apy should be individualized on the basis of considerations of 
ASCVD risk-reduction benefits, the potential for adverse effects 
and drug–drug interactions, and patient preferences (Figure 4).
4.6. Primary Prevention in Individuals Without 
Diabetes and With LDL-C 70 to 189 mg/dL
In individuals 40 to 75 years of age with LDL-C 70 to 189 
mg/dL who do not have clinical ASCVD or diabetes, initia-
tion of statin therapy based on estimated 10-year ASCVD risk 
is recommended, regardless of sex, race, or ethnicity (Section 
4.7). Point estimates of statin-associated reductions in the rela-
tive risk of ASCVD in primary prevention are similar for both 
women and men. There also is no evidence that the ASCVD 
risk-reduction benefit or adverse-effect profiles differ by race.
To better identify those individuals without ASCVD who 
would most benefit from statin therapy to reduce ASCVD risk, 
data were used from the 3 exclusively primary-prevention RCTs 
that included individuals with LDL-C levels <190 mg/dL, 
almost all of whom had LDL-C levels ≥70 mg/dL.17,18,49 From 
these trials, an estimate of the expected 10-year ASCVD 
event rates was derived from the placebo groups. The rates 
of excess adverse events in the statin treatment groups were 
obtained from meta-analyses of statin RCTs. A high level of 
evidence for an ASCVD risk-reduction benefit from initiation 
of moderate- or high-intensity statin therapy in individuals 
40 to 75 years of age with ≥7.5% estimated 10-year ASCVD 
risk was found (Section 4.7). The reduction in ASCVD risk 
clearly outweighs the potential for adverse effects (Table 7). 
Thus, it is recommended that individuals 40 to 75 years of 
age, who are not already candidates for statin therapy on the 
basis of the presence of clinical ASCVD, diabetes, or LDL-C 
≥190 mg/dL, receive statin therapy if they have a ≥7.5% esti-
mated 10-year risk for ASCVD and LDL-C 70 to 189 mg/
dL. Although only 1 exclusively primary-prevention RCT 
included individuals with LDL-C 70 to <100 mg/dL, the 
Cholesterol Treatment Trialists 2010 meta-analysis found 
a relative reduction in ASCVD events of similar magnitude 
across the spectrum of LDL-C levels ≥70 mg/dL.20 Given 
that the relative risk reduction is similar across the range of 
Table 7. Rationale for the Expert Panel Approach to Primary-
Prevention Guidelines
1. Cholesterol-lowering medications, particularly statins, are efficacious  
and effective for reducing risk of initial cardiovascular events.
2. Statins are associated with similar relative risk reductions for  
 cardiovascular events across the majority of primary-prevention  
patient groups studied.*
3. The extent of relative risk reduction for ASCVD is proportional to the  
 degree of LDL-C lowering observed on statin therapy. Therefore, more 
intensive statin therapy could reduce risk more than moderate- or  
lower-intensity statin therapy.
4. According to consistent findings, the absolute benefit in ASCVD risk  
 reduction is proportional to the baseline risk of the patient group or 
individual and to the intensity of statin therapy.
5. Patients or groups at higher baseline absolute risk, therefore, will  
 derive greater absolute benefit from initiation of statin therapy over  
a period of 5 to 10 years.
6. The absolute risk for adverse outcomes, including a small excess in  
 cases of newly diagnosed diabetes, also appears to be proportional to 
the intensity of statin therapy. However, the adverse outcome of incident 
(or earlier diagnosis of) diabetes must be weighed in the context of the 
potentially fatal or debilitating occurrence of MI or stroke that could be 
prevented by statin therapy.
7. The Expert Panel emphasizes that the occurrence of a major ASCVD  
 event (MI or stroke) represents a much greater harm to health status  
than does an increase in blood glucose leading to a diagnosis of diabetes. 
The net absolute benefit of statin therapy can be considered as a com-
parison of the absolute risk reduction for ASCVD with the absolute excess 
risks, including that for diabetes. Benefit also could be understood as a 
comparison of the number of statin-treated patients that would result in 
the prevention of 1 case of major ASCVD (NNT) with the number of statin-
treated patients that would result in 1 excess case of diabetes (NNH).
8. Because the absolute benefit in terms of ASCVD risk reduction depends  
 on the baseline absolute risk for ASCVD, the absolute benefit from initiation 
of statin therapy is lower and would approach the risk for adverse effects in 
patients with lower baseline levels of predicted ASCVD risk.
9. Available RCT evidence indicates a clear net absolute benefit of initiation  
 of moderate-to-intensive statin therapy at a baseline estimated 10-year 
ASCVD risk of ≥7.5%.
10. Available RCT evidence indicates that when baseline ASCVD risk is 5.0%  
 to <7.5%, there is still net absolute benefit with moderate-intensity statin 
therapy. However, the tradeoffs between the ASCVD risk-reduction benefit 
and adverse effects are less clear. Thus, a clinician-patient discussion is 
even more important for individuals with this range of ASCVD risk. The net 
benefit of high-intensity statin therapy may be marginal in such individuals.
Conclusion
On the basis of the above tenets and its review of the evidence, this  
 guideline recommends initiation of moderate or intensive statin therapy for 
patients who are eligible for primary ASCVD prevention and have a predicted 
10-year “hard” ASCVD risk of ≥7.5%. This guideline recommends that 
initiation of moderate-intensity statin therapy be considered for patients with 
predicted 10-year “hard” ASCVD risk of 5.0% to <7.5%.
*Available evidence suggests that initiation of statin therapy might not 
achieve a significant reduction of CVD risk in patients with higher classes of 
NYHA heart failure or who are receiving maintenance hemodialysis.
ASCVD indicates atherosclerotic cardiovascular disease; CVD, cardiovascular 
disease; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; 
NNH, number needed to harm; NNT, number needed to treat; NYHA, New York 
Heart Association; and RCT, randomized controlled trial.
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LDL-C 70 to 189 mg/dL, the absolute benefit of statin ther-
apy in primary prevention is determined by the global risk 
estimate using all the risk factor information and is reflected 
in the estimated 10-year ASCVD risk.
A conservative estimate of adverse events includes excess 
cases of new-onset diabetes and rare cases of myopathy and 
hemorrhagic stroke. The rate of excess diabetes varies by statin 
intensity. For moderate-intensity statins, approximately 0.1 
excess case of diabetes per 100 statin-treated individuals per 
year has been observed, and for high-intensity statins, approxi-
mately 0.3 excess case of diabetes per 100 statin-treated indi-
viduals per year has been observed.52,81 The long-term adverse 
effects of statin-associated cases of diabetes over a 10-year 
period are unclear and are unlikely to be equivalent to an MI, 
stroke, or ASCVD death. Myopathy (~0.01 excess case per 
100) and hemorrhagic stroke (~0.01 excess case per 100) make 
minimal contributions to excess risk from statin therapy.13
Although a similar level of evidence of a reduction in 
ASCVD events from moderate- and high-intensity statin ther-
apy is present for those with a 5% to <7.5% estimated 10-year 
ASCVD risk, the potential for adverse effects may outweigh 
the potential for ASCVD risk-reduction benefit when high-
intensity statin therapy is used in this risk group. However, for 
moderate-intensity statin therapy, the ASCVD risk reduction 
clearly exceeds the potential for adverse effects.
Before initiating statin therapy for the primary preven-
tion of ASCVD in adults with ≥7.5% or 5% to <7.5% esti-
mated 10-year ASCVD risk, it is reasonable for clinicians and 
patients to engage in a discussion of the proposed therapy. 
This discussion should include the potential for ASCVD ben-
efit, the potential for adverse effects and drug–drug interac-
tions, and consideration of patient preferences for treatment.
No primary-prevention RCT data were available for indi-
viduals 21 to 39 years of age, and few data were available for 
individuals >75 years of age. Additionally, in individuals 40 to 
75 years of age with <5% estimated 10-year ASCVD risk, the 
net benefit from statin therapy over a 10-year period may be 
small. Therefore, in adults with LDL-C <190 mg/dL who are 
not otherwise identified in a statin benefit group or for whom a 
risk-based treatment decision is uncertain after quantitative risk 
assessment, clinician knowledge, experience, and skill (“the 
art of medicine”) and patient preferences all contribute to the 
decision to initiate statin therapy.82 Before initiation of statin 
therapy, the clinician-patient discussion should include con-
sideration of the potential for ASCVD risk-reduction benefits, 
adverse effects, and drug–drug interactions. Additional factors 
may also be considered to inform treatment decision making 
in selected individuals. Factors that can contribute to assess-
ment of ASCVD risk include primary LDL-C ≥160 mg/dL 
or other evidence of genetic hyperlipidemias; family his-
tory of premature ASCVD with onset <55 years of age in a 
first-degree male relative or <65 years of age in a first-degree 
female relative; high-sensitivity C-reactive protein ≥2 mg/L, 
coronary artery calcium score ≥300 Agatston units or ≥75th 
percentile for age, sex, and ethnicity (for additional informa-
tion, see http://www.mesa-nhlbi.org/CACReference.aspx); 
ankle-brachial index <0.9; or elevated lifetime risk of ASCVD. 
Additional factors that might aid in individual risk assessment 
could be identified in the future.
For an individual <40 years of age, the 10-year horizon might 
not be optimal for predicting lifetime risk of ASCVD (see “2013 
ACC/AHA Guideline on the Assessment of Cardiovascular 
Risk”).11 Future RCTs will be needed to determine the optimal 
age at which to initiate statin therapy to reduce ASCVD risk, 
as well as to determine the optimum duration of statin therapy.
4.7. Risk Assessment in Primary Prevention
To estimate more closely the total burden of ASCVD, this guide-
line recommends a comprehensive assessment of the estimated 
10-year risk for an ASCVD event that includes both CHD and 
stroke. This is in contrast to the use of an estimated 10-year risk 
for hard CHD (defined as nonfatal MI and CHD death).83
This guideline recommends using the new Pooled Cohort 
Risk Assessment Equations developed by the Risk Assessment 
Work Group to estimate the 10-year ASCVD risk (defined as 
first-occurrence nonfatal and fatal MI and nonfatal and fatal 
stroke) for the identification of candidates for statin therapy (see 
http://my.americanheart.org/cvriskcalculator and http://www.
cardiosource.org/en/Science-And-Quality/Practice-Guidelines-
and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx 
for risk calculator). These equations should be used to predict 
stroke as well as CHD events in non-Hispanic, Caucasian, and 
African-American women and men 40 to 79 years of age with or 
without diabetes who have LDL-C levels 70 to 189 mg/dL and 
are not receiving statin therapy. A more complete discussion of 
risk assessment is provided in the Full Panel Report Supplement.
This guideline does not require specific risk factor counting 
for risk assessment or the use of RCT risk factor inclusion crite-
ria to determine statin eligibility. Rather, a global ASCVD risk 
assessment to guide initiation of statin therapy was chosen for 
several important reasons (see rationale in Table 7 and further 
discussion in Section 7.3 of the Full Panel Report Supplement): 
1) The Cholesterol Treatment Trialists individual-level meta-
analyses were used to evaluate the effect of statins in various 
important patient subgroups, including risk factor cutpoints used 
for RCT eligibility. The Expert Panel found that statin therapy 
reduces ASCVD events regardless of risk factor characteristics 
in both primary and secondary prevention. Therefore, the ratio-
nale for using fixed cutpoints to determine whether statin ther-
apy should be used is refuted by a consideration of the total body 
of evidence. 2) Use of absolute ASCVD risk facilitates a quanti-
tative assessment of the potential for an ASCVD risk-reduction 
benefit as compared with the potential for adverse effects. 3) Use 
of an RCT eligibility criteria–based approach results in failure to 
identify a substantial proportion of higher-risk individuals who 
could benefit from statin therapy and overidentification of very-
low-risk individuals who might not experience a net benefit from 
statin therapy over a 10-year period.
4.8. Heart Failure and Hemodialysis
No recommendation was made with regard to the initiation or 
continuation of statin therapy in 2 specific groups: 1) individu-
als with New York Heart Association class II–IV heart failure, 
and 2) individuals undergoing maintenance hemodialysis. In 
the 4 RCTs reviewed that specifically addressed statin treat-
ment in these groups, there were individuals with and with-
out heart disease.84–87 Although statin therapy did not reduce 
ASCVD events in 2 RCTs for each condition,84–87 there was 
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insufficient information on which to base recommendations 
for or against statin treatment. Future research may identify 
subgroups of patients with these conditions that may benefit 
from statin therapy. In individuals with these conditions, the 
potential for ASCVD risk-reduction benefits, adverse effects, 
and drug–drug interactions, along with other cautions and 
contraindications to statin therapy and choice of statin dose, 
must also be considered by the treating clinician.
5. Safety: Recommendations
See safety recommendations for statins (Table 8) and non-
statin drugs (Table 9).
RCT data were also used to examine the safety of lipid 
medications. From the statin RCTs and meta-analyses, patient 
characteristics and monitoring strategies were identified that 
should enhance the safe use of high- and moderate-intensity 
statin therapy. Patient characteristics that may influence statin 
Table 8. Statin Safety Recommendations
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
Safety
1. To maximize the safety of statins, selection of the appropriate statin and dose in  
 men and nonpregnant/nonnursing women should be based on patient characteristics,  
level of ASCVD* risk, and potential for adverse effects. Moderate-intensity statin  
therapy should be used in individuals in whom high-intensity statin therapy  
would otherwise be recommended when characteristics predisposing them to  
statin-associated adverse effects are present.
Characteristics predisposing individuals to statin adverse effects include but are not  
 limited to:
•	Multiple or serious comorbidities, including impaired renal or hepatic function.
•	History of previous statin intolerance or muscle disorders.
•	Unexplained ALT elevations ≥3 times ULN.
•	Patient characteristics or concomitant use of drugs affecting statin metabolism.
•	Age >75 years.
Additional characteristics that could modify the decision to use higher statin  
intensities might include but are not limited to:
•	History of hemorrhagic stroke.
•	Asian ancestry.
A (Strong) 46–55 I B
2a. CK should not be routinely measured in individuals receiving statin therapy. A (Strong) 45,49–51,54,55 III: No Benefit A
2b. Baseline measurement of CK is reasonable for individuals believed to be at  
 increased risk for adverse muscle events because of a personal or family history  
of statin intolerance or muscle disease, clinical presentation, or concomitant drug 
therapy that might increase the risk of myopathy.
E (Expert Opinion) — IIa C88
2c. During statin therapy, it is reasonable to measure CK in individuals with muscle  
 symptoms, including pain, tenderness, stiffness, cramping, weakness, or  
generalized fatigue.
E (Expert Opinion) — IIa C88
3a. Baseline measurement of hepatic transaminase levels (ALT) should be performed  
before initiation of statin therapy.
B (Moderate) 46,52,53 I† B
3b. During statin therapy, it is reasonable to measure hepatic function if symptoms  
 suggesting hepatotoxicity arise (eg, unusual fatigue or weakness, loss of appetite, 
abdominal pain, dark-colored urine, or yellowing of the skin or sclera).
E (Expert Opinion) — IIa C89
4. Decreasing the statin dose may be considered when 2 consecutive values of  
LDL-C levels are <40 mg/dL.
C (Weak) 45 IIb C
5. It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of  
simvastatin to 80 mg daily.
B (Moderate) 6,54 III: Harm A67,90
6. Individuals receiving statin therapy should be evaluated for new-onset diabetes  
 according to the current diabetes screening guidelines.91 Those who develop  
diabetes during statin therapy should be encouraged to adhere to a heart-healthy  
dietary pattern, engage in physical activity, achieve and maintain a healthy body  
weight, cease tobacco use, and continue statin therapy to reduce their risk of  
ASCVD events.
B (Moderate) 44 I‡ B
7. For individuals taking any dose of statins, it is reasonable to use caution in  
 individuals >75 years of age, as well as in individuals who are taking concomitant 
medications that alter drug metabolism, taking multiple drugs, or taking drugs for 
conditions that require complex medication regimens (eg, those who have undergone 
solid organ transplantation or are receiving treatment for HIV). A review of the 
manufacturer’s prescribing information may be useful before initiation of  
any cholesterol-lowering drug.
E (Expert Opinion) — IIa C16,64–70,89,92–94
(Continued)
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safety include but are not limited to: multiple or serious 
comorbidities, including impaired renal or hepatic function; 
a history of previous statin intolerance or muscle disorders; 
concomitant use of drugs affecting statin metabolism; a his-
tory of hemorrhagic stroke; and age >75 years. Asian ancestry 
may also influence the initial choice of statin intensity.
This guideline recommends against routine measurement 
of creatine kinase in individuals receiving statin therapy. This 
measurement should be reserved for those with muscle symp-
toms. However, measurement of a baseline creatine kinase 
may be useful in those at increased risk of adverse muscle 
events. Such individuals include those with a personal or fam-
ily history of statin intolerance or muscle disease, clinical pre-
sentation, or concomitant drug therapy that might increase the 
likelihood of myopathy.
Expert recommendations are also provided for manag-
ing muscle symptoms while a patient is on statin therapy. 
These useful management suggestions were derived from 
other clinical trial data and clinical experience to enhance the 
safety and tolerability of statin therapy. Consistent with the 
protocols of the RCTs, patients should be asked at each visit, 
both before and after initiation of statin therapy, about muscle 
symptoms such as muscle weakness or fatigue, aching, pain, 
tenderness, cramps, or stiffness. The recommended approach 
for management of muscle symptoms is described in Table 8, 
Recommendation 8.
This guideline recommends that baseline measurement of 
transaminase (alanine transaminase; ALT) levels should be 
performed before initiation of statin therapy. This approach 
was taken in the RCTs reviewed for this report. There is 
no recommendation to monitor transaminase (ALT) levels 
because ALT monitoring was performed in the RCTs, and 
there was no significant difference between placebo groups 
and statin treatment groups in the rates of ALT elevations. In 
addition, the US Food and Drug Administration has indicated 
that if the baseline hepatic transaminases are normal, further 
Table 8. Continued
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
8. It is reasonable to evaluate and treat muscle symptoms, including pain,  
 tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients 
according to the following management algorithm:
•	To avoid unnecessary discontinuation of statins, obtain a history of prior or current  
muscle symptoms to establish a baseline before initiation of statin therapy.
•	If unexplained severe muscle symptoms or fatigue develop during statin therapy,  
 promptly discontinue the statin and address the possibility of rhabdomyolysis by 
evaluating CK and creatinine and performing urinalysis for myoglobinuria.
•	If mild to moderate muscle symptoms develop during statin therapy:
– Discontinue the statin until the symptoms can be evaluated.
– Evaluate the patient for other conditions that might increase the risk for muscle  
 symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic 
disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D 
deficiency, or primary muscle diseases).
– If muscle symptoms resolve, and if no contraindication exists, give the patient  
 the original or a lower dose of the same statin to establish a causal relationship 
between the muscle symptoms and statin therapy.
– If a causal relationship exists, discontinue the original statin. Once muscle  
symptoms resolve, use a low dose of a different statin.
– Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
– If, after 2 months without statin treatment, muscle symptoms or elevated CK  
 levels do not resolve completely, consider other causes of muscle symptoms 
listed above.
– If persistent muscle symptoms are determined to arise from a condition  
unrelated to statin therapy, or if the predisposing condition has been treated, 
resume statin therapy at the original dose.
E (Expert Opinion) — IIa B15,88,96–98
9. For individuals presenting with a confusional state or memory impairment while on  
 statin therapy, it may be reasonable to evaluate the patient for nonstatin causes, such 
as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in 
addition to the possibility of adverse effects associated with statin drug therapy.
E (Expert Opinion) — IIb C38,89,99,100
*Based on the presence of clinical ASCVD, diabetes, LDL-C ≥190 mg/dL, or level of estimated 10-year ASCVD risk.
†Individuals with elevated ALT levels (usually >1.5 or 2 times ULN) were excluded from RCT participation. Unexplained ALT ≥3 times ULN is a contraindication to 
statin therapy as listed in manufacturer’s prescribing information.
‡Statin use is associated with a very modest excess risk of new-onset diabetes in RCTs and meta-analyses of RCTs (ie, ~0.1 excess cases per 100 individuals treated 
for 1 year with moderate-intensity statin therapy and ~0.3 excess cases per 100 individuals treated for 1 year with high-intensity statin therapy. The increased risk of new-
onset diabetes appears to be confined to those with risk factors for diabetes. These individuals are also at higher risk of ASCVD because of these risk factors. Therefore, 
if a statin-treated individual develops diabetes as detected by current diabetes screening guidelines, he or she should be counseled to adhere to a heart-healthy dietary 
pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce the risk of ASCVD events.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CK, 
creatine kinase; COR, Class of Recommendation; NHLBI, National Heart, Lung, and Blood Institute; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; 
RCTs, randomized controlled trials; ULN, upper limit of normal; and —, not applicable.
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Table 9. Nonstatin Safety Recommendations
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
Safety of Niacin
1. Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric  
 acid should be obtained before initiation of niacin, and again during up-titration to a 
maintenance dose and every 6 months thereafter.
B (Moderate) 77 I B
2. Niacin should not be used if:
•	Hepatic transaminase elevations are higher than 2 to 3 times ULN. A (Strong) 79 III: Harm B
•	Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout, or  
 unexplained abdominal pain or gastrointestinal symptoms occur.
B (Moderate) 78,79 III: Harm B
•	New-onset atrial fibrillation or weight loss occurs. C (Weak) 80 III: Harm B
3. In individuals with adverse effects from niacin, the potential for ASCVD benefits and the  
 potential for adverse effects should be reconsidered before reinitiation of niacin therapy.
E (Expert) — I B9,101–104
4. To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to:
•	Start niacin at a low dose and titrate to a higher dose over a period of weeks as  
tolerated.
•	Take niacin with food or premedicate with aspirin 325 mg 30 minutes before niacin  
dosing to alleviate flushing symptoms.
•	If an extended-release preparation is used, increase the dose of extended-release  
 niacin from 500 mg to a maximum of 2000 mg/day over 4 to 8 weeks, with the dose 
of extended-release niacin increasing not more than weekly.
•	If immediate-release niacin is chosen, start at a dose of 100 mg 3 times daily and  
up-titrate to 3 g/day, divided into 2 or 3 doses.
E (Expert) — IIa C9,101–104
Safety of BAS
1. BAS should not be used in individuals with baseline fasting triglyceride levels  
 ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations 
might occur. (A fasting lipid panel should be obtained before BAS is initiated,  
3 months after initiation, and every 6 to 12 months thereafter.)
C (Weak) 60 III: Harm B
2. It is reasonable to use BAS with caution if baseline triglyceride levels are 250 to  
 299 mg/dL, and evaluate a fasting lipid panel in 4 to 6 weeks after initiation.  
Discontinue the BAS if triglycerides exceed 400 mg/dL.
E (Expert) — IIa C105
Safety of Cholesterol-Absorption Inhibitors
1. It is reasonable to obtain baseline hepatic transaminases before initiation of  
 ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase  
levels as clinically indicated, and discontinue ezetimibe if persistent ALT elevations  
≥3 times ULN occur.
C (Weak) 61–64 IIa B
Safety of Fibrates
1. Gemfibrozil should not be initiated in patients on statin therapy because of an  
increased risk for muscle symptoms and rhabdomyolysis.
B (Moderate) 46 III: Harm B
2. Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin  
 only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides 
are ≥500 mg/dL are judged to outweigh the potential risk for adverse effects.
E (Expert) — IIb C14
3. Renal status should be evaluated before fenofibrate initiation, within 3 months after  
 initiation, and every 6 months thereafter. Assess renal safety with both a serum 
creatinine level and an eGFR based on creatinine.
B (Moderate) 66,67 I B
•	Fenofibrate should not be used if moderate or severe renal impairment, defined as  
eGFR <30 mL/min per 1.73 m2, is present.
•	If eGFR is between 30 and 59 mL/min per 1.73 m2, the dose of fenofibrate should  
not exceed 54 mg/day.*
•	If, during follow-up, the eGFR decreases persistently to ≤30 mL/min per 1.73 m2,  
fenofibrate should be discontinued.
III: Harm B
Safety of Omega-3 Fatty Acids
1. If EPA and/or DHA are used for the management of severe hypertriglyceridemia,  
 as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal 
disturbances, skin changes, and bleeding.
C (Weak) 70 IIa B
*Consult the manufacturer's prescribing information as there are several forms of fenofibrate available.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, 
bile acid sequestrants; COR, Class of Recommendation; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; eGFR, estimated glomerular filtration rate; LOE, Level 
of Evidence; NHLBI, National Heart, Lung, and Blood Institute; ULN, upper limit of normal; and —, not applicable.
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hepatic monitoring is not needed. During statin therapy, it is 
reasonable to measure hepatic function if symptoms suggest-
ing hepatotoxicity arise (eg, unusual fatigue or weakness, loss 
of appetite, abdominal pain, dark-colored urine, or yellowing 
of the skin or sclera).
Decreasing the statin dose may be considered when 2 con-
secutive values of LDL-C are <40 mg/dL. This recommenda-
tion was based on the approach taken in 2 RCTs. However, no 
data were identified that suggest an excess of adverse events 
occurred when LDL-C levels were below this level.
Statins modestly increase the excess risk of type 2 diabetes 
in individuals with risk factors for diabetes. The potential for 
an ASCVD risk-reduction benefit outweighs the excess risk of 
diabetes in all but the lowest-risk individuals (Section 4.5). All 
individuals receiving statins should be counseled on healthy-
lifestyle habits. Individuals receiving statin therapy should 
be evaluated for new-onset diabetes according to the current 
diabetes screening guidelines.91 Those who develop diabetes 
during statin therapy should be encouraged to adhere to a heart-
healthy dietary pattern, engage in physical activity, achieve and 
maintain a healthy body weight, cease tobacco use, and con-
tinue statin therapy to reduce their risk of ASCVD events.
Statins are listed as pregnancy category X and should not be 
used in women of childbearing potential unless these women 
are using effective contraception and are not nursing.
For individuals taking any dose of statins, it is reasonable 
to use caution in individuals >75 years of age, as well as in 
individuals who are taking concomitant medications that alter 
drug metabolism, taking multiple drugs, or taking drugs for 
conditions that require complex medication regimens (eg, 
those who have undergone solid organ transplantation or are 
receiving treatment for HIV). A review of the manufacturer’s 
prescribing information might be useful before initiation of 
any cholesterol-lowering drug, because RCTs considered 
defined populations and many patients in everyday practice 
would not qualify for clinical trials. Thus, clinicians should 
also consult other sources of safety data, such as pharmacists, 
drug information centers, and manufacturers’ prescribing 
information on a regular basis for up-to-date guidance about 
lipid medications and medication interactions.
Statins used in combination with other cholesterol-lowering 
drug therapies might require more intensive monitoring. The 
safety of nonstatin agents was reviewed, and that information 
is included in Table 9 and the Full Panel Report Supplement. 
Warnings about the use of cholesterol-lowering agents in 
pregnancy and lactation also apply to nonstatins, and the man-
ufacturer's prescribing information should be consulted.
6. Managing Statin Therapy: 
Recommendations
See Table 10 for a summary of recommendations for monitor-
ing, optimizing, and addressing insufficient response to statin 
therapy.
6.1. Monitoring Statin Therapy
A high level of RCT evidence supports the use of an initial fast-
ing lipid panel (total cholesterol, triglycerides, HDL-C, and 
calculated LDL-C), followed by a second lipid panel 4 to 12 
weeks after initiation of statin therapy, to determine a patient’s 
adherence. Thereafter, assessments should be performed every 
3 to 12 months as clinically indicated. Adherence to both med-
ication and lifestyle regimens are required for ASCVD risk 
reduction. After statin therapy has been initiated, some indi-
viduals experience unacceptable adverse effects when taking 
the recommended intensity of statin therapy. Once the severity 
and association of adverse effects with statin therapy has been 
established, and once factors potentially contributing to statin 
intolerance are resolved, the patient should be given lower 
doses of the same statin or an alternative appropriate statin, 
until a statin and dose that have no adverse effects have been 
identified (Table 8, Recommendation 8).
See Figure 5 for a flow diagram on monitoring statin 
response for the initiation of nonstatin therapy.
6.2. Optimizing Statin Therapy
Although high-intensity statin therapy reduces ASCVD events 
more than moderate-intensity statin therapy, lower-intensity 
statin therapy has also been shown to reduce ASCVD events, 
although to a lesser degree. Therefore, individuals who merit 
guideline-recommended statin therapy should be treated with 
the maximum-appropriate intensity of a statin that does not 
cause adverse effects.
6.3. Insufficient Response to Statin Therapy
6.3.1. Testing
The evidence is less clear with regard to the most appropri-
ate tests for determining whether an anticipated therapeutic 
response to statin therapy has occurred on the maximally 
tolerated dose. RCT evidence to support the use of specific 
LDL-C or non–HDL-C targets was not identified. The focus is 
on the intensity of the statin therapy, but as an aid to monitor-
ing response to therapy and adherence, it is reasonable to use 
the following as indicators of anticipated therapeutic response 
to statin therapy:
•	 High-intensity statin therapy generally results in an 
average LDL-C reduction of ≥50% from the untreated 
baseline.
•	 Moderate-intensity statin therapy generally results in 
an average LDL-C reduction of 30% to <50% from the 
untreated baseline.
•	 LDL-C levels and percent reduction are to be used only 
to assess response to therapy and adherence. They are 
not to be used as performance standards.
In those already on a statin, in whom the baseline LDL-C is 
unknown, an LDL-C <100 mg/dL was observed in most indi-
viduals receiving high-intensity statin therapy in RCTs.
However, there are many limitations of using LDL-C 
<100 mg/dL as a fixed target. If a moderate- or low-intensity 
statin results in an LDL-C level <100 mg/dL in a patient with 
ASCVD, the evidence suggests that a high-intensity statin, 
if tolerated, provides a greater reduction in ASCVD events. 
Conversely, in those with LDL-C levels slightly >100 mg/dL 
on a high-intensity statin, some options such as niacin might 
require down-titration of the statin intensity in an effort to 
improve safety. This would result in a suboptimal intensity 
of evidence-based statin therapy. Additional limitations to 
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using LDL-C treatment targets are discussed in the Full Panel 
Report Supplement.
No evidence was found that titration or combination-drug ther-
apy to achieve specific LDL-C or non–HDL-C levels or percent 
reductions improved ASCVD outcomes. Therefore, this guide-
line does not recommend their use as performance measures.
The percent LDL-C reduction may not only indicate 
adherence, but also may reflect biological variability in the 
response to statin therapy. This acknowledges that some indi-
viduals may have less than an average response. Attention to 
adherence of statin and lifestyle therapy and evaluation and 
treatment of secondary causes (Table 6) that might elevate 
LDL-C, may address less-than-anticipated responses to a spe-
cific statin dosage. Whether the dose of statin therapy should 
be increased on the basis of a less-than-anticipated average 
response should be left to clinical judgment.
6.3.2. Nonstatins Added to Statins or in Statin-Intolerant 
Individuals
Adherence to lifestyle changes and to statin therapy should be 
reemphasized before the addition of a nonstatin drug is consid-
ered (Figure 5). RCTs evaluating the ASCVD event reductions 
Table 10. Recommendations for Monitoring, Optimizing, and Addressing Insufficient Response to Statin Therapy
Recommendations NHLBI Grade
NHLBI Evidence 
Statements ACC/AHA COR ACC/AHA LOE
Monitoring Statin Therapy
1. Adherence to medication and lifestyle, therapeutic response to statin therapy,  
 and safety should be regularly assessed. This should also include a fasting lipid  
panel performed within 4–12 weeks after initiation or dose adjustment, and every 
3–12 months thereafter. Other safety measurements should be measured as  
clinically indicated.
A (Strong) 45 I A
Optimizing Statin Therapy
1. The maximum tolerated intensity of statin should be used in individuals for  
whom a high- or moderate-intensity statin is recommended but not tolerated.
B (Moderate) 25,26,27,45 I* B
Insufficient Response to Statin Therapy
1. In individuals who have a less-than-anticipated therapeutic response or  
 are intolerant of the recommended intensity of statin therapy, the following  
should be performed:
•	Reinforce medication adherence.
•	Reinforce adherence to intensive lifestyle changes.
•	Exclude secondary causes of hyperlipidemia.
A (Strong) 45 I A
2. It is reasonable to use the following as indicators of anticipated therapeutic  
 response to the recommended intensity of statin therapy. Focus is on the  
intensity of the statin therapy. As an aid to monitoring:
•	High-intensity statin therapy† generally results in an average LDL-C  
 reduction of ≥50% from the untreated baseline.
•	Moderate-intensity statin therapy generally results in an average  
 LDL-C reduction of 30% to <50% from the untreated baseline.
•	LDL-C levels and percents reduction are to be used only to assess response to  
therapy and adherence. They are not to be used as performance standards.
E (Expert Opinion) — IIa B46–48,78,106,107
3. In individuals at higher ASCVD risk receiving the maximum tolerated intensity  
 of statin therapy who continue to have a less-than-anticipated therapeutic  
response, addition of nonstatin cholesterol-lowering drug(s) may be considered  
if the ASCVD risk-reduction benefits outweigh the potential for adverse effects.
•	Higher-risk individuals include:
•	Individuals with clinical ASCVD‡ <75 years of age.
•	Individuals with baseline LDL-C ≥190 mg/dL.
•	Individuals 40–75 years of age with diabetes.
Preference should be given to nonstatin cholesterol-lowering drugs shown to  
reduce ASCVD events in RCTs.
E (Expert Opinion) — IIb C9,14,108–110
4. In individuals who are candidates for statin treatment but are completely statin  
 intolerant, it is reasonable to use nonstatin cholesterol-lowering drugs that  
have been shown to reduce ASCVD events in RCTs if the ASCVD risk-reduction  
benefits outweigh the potential for adverse effects.
E (Expert Opinion) — IIa B88,101,111–116
*Several RCTs found that low-intensity and low-moderate–intensity statin therapy reduced ASCVD events. In addition, the Cholesterol Treatment Trialists meta-
analyses found that each 39-mg/dL reduction in LDL-C reduces ASCVD risk by 22%. Therefore, the Panel considered that submaximal statin therapy should be used to 
reduce ASCVD risk in those unable to tolerate moderate- or high-intensity statin therapy.
†In those already on a statin, in whom baseline LDL-C is unknown, an LDL-C level <100 mg/dL was observed in most individuals receiving high-intensity statin therapy.
‡Clinical ASCVD includes acute coronary syndromes, or a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, 
stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin.
ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; COR, Class of Recommendation; LDL-C, 
low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; RCTs, randomized controlled trials; and —, not applicable.
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from nonstatins used as monotherapy were reviewed, as were 
RCTs evaluating the additional reduction in ASCVD events 
from nonstatin therapy added to statin therapy. The Expert 
Panel could find no data supporting the routine use of non-
statin drugs combined with statin therapy to further reduce 
ASCVD events. In addition, no RCTs that assessed ASCVD 
outcomes in statin-intolerant patients were found.
Clinicians treating high-risk patients who have a less-
than-anticipated response to statins, who are unable to tol-
erate a less-than-recommended intensity of a statin, or who 
are completely statin intolerant, may consider the addition 
of a nonstatin cholesterol-lowering therapy. High-risk indi-
viduals include those with ASCVD, those with LDL-C ≥190 
mg/dL, and those with diabetes 40–75 years of age. In this 
situation, this guideline recommends clinicians preferentially 
prescribe drugs that have been shown in RCTs to provide 
ASCVD risk-reduction benefits that outweigh the potential 
for adverse effects and drug–drug interactions, and consider 
patient preferences.
7. Selected Clinical and Population Subgroups
7.1. Sex and Racial and Ethnic Subgroups
Because the RCT evidence shows that the absolute benefit 
of statin treatment is proportional to baseline ASCVD risk, 
treatment decisions for women and racial and ethnic sub-
groups should be based on the level of ASCVD risk. This con-
clusion is a departure from previous approaches that focused 
on LDL-C levels to guide treatment decisions. Statin treatment 
based on estimated 10-year ASCVD risk avoids the overtreat-
ment of lower-risk groups, such as younger, non-Hispanic 
white women who, despite moderate elevations in LDL-C, 
are typically not at significantly increased risk for ASCVD in 
the next 10 years in the absence of substantial risk factor bur-
den. However, ignoring the increased ASCVD risk in African 
American women and men might result in the undertreatment 
of some individuals who are at significantly higher ASCVD 
risk at the same LDL-C level. Thus, this guideline recom-
mends statin therapy for individuals in whom it is most likely 
to provide ASCVD risk reduction on the basis of the estimated 
10-year risk of ASCVD.
7.2. Individuals >75 Years of Age
Fewer people >75 years of age were enrolled in the statin 
RCTs reviewed. RCT evidence does support the continuation 
of statins beyond 75 years of age in persons who are already 
taking and tolerating these drugs. A larger amount of data sup-
ports the use of moderate-intensity statin therapy for second-
ary prevention in individuals with clinical ASCVD who are 
>75 years of age. However, the limited information available 
Figure 5. Statin Therapy: Monitoring Therapeutic Response and Adherence. Colors correspond to the Classes of Recommendation in 
Table 1. *Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level ≥220 mg/dL may indicate genetic hypercholesterol-
emia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are ≥500 mg/dL, a fasting lipid panel is required. 
†In those already on a statin, in whom baseline LDL-C is unknown, an LDL-C <100 mg/dL was observed in most individuals receiving 
high-intensity statin therapy in RCTs. ‡See Section 6.3.1. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipo-
protein cholesterol; and RCTs, randomized clinical trials.
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did not clearly support initiation of high-intensity statin ther-
apy for secondary prevention in individuals >75 years of age.
Few data were available to indicate an ASCVD event reduc-
tion benefit in primary prevention among individuals >75 
years of age who do not have clinical ASCVD. Therefore, 
initiation of statins for primary prevention of ASCVD in indi-
viduals >75 years of age requires consideration of additional 
factors, including increasing comorbidities, safety consider-
ations, and priorities of care. The Pooled Cohort Equations 
can also provide information on expected 10-year ASCVD 
risk for those 76 to 79 years of age that may inform the treat-
ment decision. These factors may influence decisions about 
cholesterol-lowering drug therapy, especially in the primary-
prevention setting. Accordingly, a discussion of the potential 
ASCVD risk-reduction benefits, risk of adverse effects, drug–
drug interactions, and consideration of patient preferences 
should precede the initiation of statin therapy for primary pre-
vention in older individuals.
8. Limitations
The evidence-based recommendations in this guideline focus 
on patient groups who are well represented in RCTs and/or 
are highly likely to have high-risk genetic conditions, so the 
recommendations are designed to inform rather than replace 
clinical judgment. However, there are other patient groups for 
which a robust evidence base is lacking but that may neverthe-
less include some persons for whom statin treatment should 
be considered (after taking patient preferences into account) 
on the basis of the potential for ASCVD benefits to exceed the 
risk of adverse events and drug–drug interactions. Clinician 
judgment is especially important for several patient groups 
for which the RCT evidence is insufficient for guiding clini-
cal recommendations. These patient groups include younger 
adults (<40 years of age) who have a low estimated 10-year 
ASCVD risk but a high lifetime ASCVD risk based on single 
strong factors or multiple risk factors. Other groups include 
those with serious comorbidities and increased ASCVD risk 
(eg, individuals with HIV or rheumatologic or inflammatory 
diseases, or who have undergone a solid organ transplantation). 
This guideline encourages clinicians to use clinical judgment 
in these situations, weighing potential benefits, adverse effects, 
drug–drug interactions, and consider patient preferences.
Previous guidelines have taken less rigorous approaches to 
identifying the evidence to support their recommendations. 
In contrast, to minimize various sources of bias, the present 
recommendations are based on data available from RCTs 
and systematic reviews and meta-analyses of RCTs that were 
graded as fair to good quality by an independent contractor 
and were reviewed by the Expert Panel, with the assistance 
of an independent methodologist. To avoid biases, evidence 
from post-hoc analyses of included RCTs, from poor-quality 
RCTs, and from observational studies was not considered. 
This approach resulted in a comprehensive set of evidence-
based clinical recommendations for the treatment of blood 
cholesterol to reduce ASCVD risk.
9. Evidence Gaps and Future Research Needs
After a systematic review of the literature, several research 
priorities are suggested that address existing evidence gaps 
and offer the greatest potential to inform and influence clinical 
practice and reduce ASCVD morbidity and mortality. High-
priority research areas are:
1. Outcomes of RCTs to evaluate statins for the primary 
prevention of ASCVD in adults >75 years of age.
2. Outcomes of RCTs to evaluate alternative treatment 
strategies for ASCVD risk reduction. These RCTs may 
compare titration to specific cholesterol or apolipopro-
tein goals versus fixed-dose statin therapy in high-risk 
patients.
3. RCTs to determine whether submaximal statin doses, 
combined with nonstatin therapies, reduce ASCVD risk 
in statin-intolerant patients.
4. Evaluation of the incidence, pathophysiology, clinical 
course, and clinical outcomes of new-onset diabetes 
associated with statin therapy.
5. Outcomes of RCTs of new lipid-modifying agents to 
determine the incremental ASCVD event-reduction ben-
efits when added to evidence-based statin therapy.
Additional research recommendations are included in the 
Full Panel Report Supplement.
10. Conclusions
These recommendations arose from careful consideration of 
an extensive body of higher-quality evidence derived from 
RCTs and systematic reviews and meta-analyses of RCTs. 
Rather than LDL-C or non–HDL-C targets, this guideline 
used the intensity of statin therapy as the goal of treatment. 
Through a rigorous process, 4 groups of individuals were 
identified for whom an extensive body of RCT evidence dem-
onstrated a reduction in ASCVD events with a good margin of 
safety from moderate- or high-intensity statin therapy:
Four Statin Benefit Groups:
1. Individuals with clinical ASCVD
2. Individuals with primary elevations of LDL-C ≥190 mg/dL
3. Individuals 40 to 75 years of age with diabetes and 
LDL-C 70 to 189 mg/dL without clinical ASCVD
4. Individuals without clinical ASCVD or diabetes who are 
40 to 75 years of age and have LDL-C 70 to 189 mg/dL 
and an estimated 10-year ASCVD risk of ≥7.5%. This 
requires a clinician-patient discussion.
Individuals in the last group can be identified by using the 
Pooled Cohort Equations for ASCVD risk prediction devel-
oped by the Risk Assessment Work Group. Lifestyle counseling 
should occur at the initial and follow-up visits as the foundation 
for statin therapy and may improve the overall risk factor profile.
Most importantly, our focus is on those individuals most 
likely to benefit from evidence-based statin therapy to reduce 
ASCVD risk. Implementation of these ASCVD risk-reduction 
guidelines will help to substantially address the large burden 
of fatal and nonfatal ASCVD in the United States. We realize 
that these guidelines represent a change from previous guide-
lines, but clinicians have become accustomed to change when 
that change is consistent with the current evidence. Continued 
accumulation of quality trial data will inform future choles-
terol treatment guidelines.
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Appendix 4. Evidence Statements
ES No. Evidence Statement
Level of 
Evidence
Recommendation(s)/
Section References
1 Data are not available regarding treatment or titration to a specific  
LDL-C goal in adults with CHD/CVD. The Expert Panel found insufficient 
evidence to support setting LDL-C goals in CHD/CVD patients.
I Secondary Prevention Conclusion after reviewing 19 RCTs  
  in CQ1 Evidence Table:
4D,87 A–Z,117 ACCORD,14 ALLIANCE,118  
  ASPEN,119 AURORA,84 CARE,73 
CORONA,85 GREACE,120 HATS,121 
HPS16, IDEAL47, LIPID,74 LIPS,122 
MIRACL,93 MUSHASHI-AMI,123 
PROVE-IT,48 SPARCL,78,107 TNT46
2 The Expert Panel did not identify any trials in adults with CHD/CVD reporting 
mean or median on-treatment non–HDL-C levels in adults with CHD/CVD.
Secondary Prevention N/A
3 LDL-C goals <130 mg/dL or <100 mg/dL in patients without  
CHD/CVD. Randomized trial data are not available regarding  
dose titration to achieve a specific LDL-C goal.
I Primary Prevention Conclusion after reviewing 6 RCTs  
 included in CQ2:
AFCAPS,17 ASPEN,119 AURORA,84  
 CARDS,75 JUPITER,49 MEGA18
4 There was insufficient evidence in women without CHD/CVD to evaluate  
the reduction in CVD risk with achieved LDL-C levels <130 mg/dL or  
<100 mg/dL.
I Primary Prevention N/A
5 The Expert Panel did not identify any trials in adults without CHD/CVD  
reporting on-treatment non–HDL-C levels in adults with CHD/CVD.
Primary Prevention N/A
6 In adults with CHD/CVD, fixed high-intensity statin treatment (atorvastatin  
40–80 mg) that achieved a mean LDL-C 67–79 mg/dL reduced the RR  
for CHD/CVD events more than fixed lower-dose statin treatment that  
achieved a mean LDL-C 97–102 mg/dL. In these trials, the mean LDL-C  
levels achieved differed by 23–30 mg/dL, or 22%–32%, between the  
2 groups. Simvastatin 80 mg did not decrease CVD events compared with 
simvastatin 20–40 mg.
See Table 4 for definitions of high, moderate, and low intensity for statins.
Higher intensity = atorvastatin 40–80 mg
Moderate intensity = atorvastatin 10 mg, pravastatin 40 mg,  
or simvastatin 20–40 mg
H Secondary Prevention Benefit:
TNT,46 IDEAL,47 PROVE-IT48
Lower LDL-C reductions, no benefit:
A–Z,117 ACCORD14
No difference in LDL-C between  
  groups: (SEARCH124 not  
included in CQ1)
7 In adults with CHD/CVD who do not have Class II–IV heart failure,  
fixed high-intensity statin (atorvastatin 80 mg) or statin-niacin  
treatment that achieved a mean LDL-C 72–79 mg/dL reduced the  
RR for CHD/CVD events compared with placebo with a mean LDL-C  
112–135 mg/dL. In these trials, the mean LDL-C levels were reduced  
by 45–57 mg/dL or by 45% (HATS121) to 53% (SPARCL107).
H Secondary Prevention SPARCL107
HATS121
MIRACL93
CORONA85–no benefit
8 In adults with CHD/CVD and diabetes, fixed high-intensity statin treatment 
(atorvastatin 80 mg) that achieved a mean LDL-C of 57–77 mg/dL  
reduced the RR for CHD/CVD events more than fixed lower-intensity  
statin treatment that achieved a mean LDL-C of 81–99 mg/dL. In these 
trials, the mean LDL-C levels achieved differed by 22–24 mg/dL, or  
22%–30%, between the 2 groups.
M to H Secondary Prevention  
  (diabetes subgroup 
included)
TNT,46,94 PROVE-IT48,125
No diabetes subgroup  
  publications found for MIRACL93  
or IDEAL47
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9 In adults ≥65 years of age with CHD/CVD, fixed high-intensity statin treatment 
(atorvastatin 80 mg) that achieved a mean LDL-C of 72 mg/dL reduced  
CHD/CVD events more than fixed lower-intensity statin treatment that 
achieved a mean LDL-C of 97 mg/dL. In this trial, the mean LDL-C levels 
achieved differed by 25 mg/dL, or 26%, between the 2 groups. In adults ≥65 
years of age with a history of stroke or TIA, higher fixed-dose statin treatment 
that achieved a mean LDL-C of 72 mg/dL reduced CHD events more than 
placebo, with a mean LDL-C of 129 mg/dL. In this trial, the mean LDL-C level 
was reduced by 61 mg/dL, or 46%, from baseline in those ≥65 years of age.
L Secondary Prevention  
  (age subgroups  
included)
TNT,46,126 SPARCL107,127
No publications by  
 age included for:
PROVE-IT48
IDEAL47
HATS121
10 In adults with CHD/CVD and CKD (excluding hemodialysis), fixed high-intensity 
statin treatment (atorvastatin 80 mg) that achieved a mean LDL-C of  
79 mg/dL reduced CHD/CVD events more than fixed lower-dose statin 
treatment that achieved a mean LDL-C of 99 mg/dL. In this trial, the mean 
LDL-C levels achieved differed by 20 mg/dL, or 20% between the 2 groups.
L Secondary Prevention  
  (CKD subgroup  
included)
TNT46,128
TNT46,129
No publications included for CKD:
PROVE-IT48
IDEAL47
11 In adults with CHD or acute coronary syndromes, more intensive-dose statin 
therapy reduced LDL-C to a greater degree (by 20 mg/dL or an additional 
20%) than less intensive-dose statin therapy or placebo and produced a 
greater reduction in CVD events.
Each 1-mmol/L (38.7-mg/dL) reduction in LDL-C reduced the RR for CVD 
events by approximately 28%.
See Table 4 for definitions of high-, moderate-, and low-intensity statin therapy.
More intensive statin therapy = atorvastatin 80 mg, simvastatin 80 mg.
Less intensive statin therapy = atorvastatin 10 mg, pravastatin 40 mg,  
or simvastatin 20–40 mg.
H Secondary Prevention CTT 201020—data from 5 trials
TNT46
IDEAL47
PROVE-IT48
A–Z117
SEARCH124 (not included in CQ1)
12 In trials of more intensive statin therapy (atorvastatin 80 mg, simvastatin 
80 mg) compared with less intensive statin therapy (atorvastatin 10 mg, 
pravastatin 40 mg, or simvastatin 20–40 mg), women with CHD or acute 
coronary syndromes experienced a similar (approximately 25%) magnitude 
of relative CVD reduction as men (approximately 29%). Women also 
experienced a similar magnitude of absolute risk reduction as men.
H Secondary Prevention  
 (women included)
CTT 201020—5 trials
TNT46
IDEAL47
PROVE-IT48
A–Z117
SEARCH124 (not included in CQ1)
13 In adults with and without CVD, in trials comparing more intensive to less 
intensive statin therapy or statin therapy with placebo/control, the relative 
CVD risk reduction was similar for those <65 years, 65 to ≤75, or  
>75 years of age. There is less information to estimate the magnitude of  
benefit in those under age 45 or over age 75 years, because fewer 
participants in these age groups were enrolled in clinical trials. More 
intensive statin therapy did not appear to reduce CVD risk, compared with 
less intensive statin therapy, in those with ASCVD and age >75 years. Statin 
therapy, compared with control (most RCTs evaluated moderate-intensity 
statin therapy), had a similar magnitude of RR reduction in those >75 as in  
those ≤75 years of age with and without ASCVD.
Statin therapy vs. control trials = atorvastatin (A) 10–20 mg, fluvastatin (F)  
80 mg, lovastatin (L) 40–80 mg, pravastatin (P) 40 mg, rosuvastatin (R)
10–20 mg, simvastatin (S) 40 mg.
See Table 4 for the Expert Panel’s definitions for high-, moderate-, and low-
intensity statin therapy.
The Panel uses moderate intensity to refer to statin drugs and doses that  
lower LDL-C by 30% to approximately 50%.
This dose refers to atorvastatin 10 mg, fluvastatin 80 mg, lovastatin 40 mg, 
pravastatin 40 mg, rosuvastatin 10 mg, and simvastatin 40 mg.
H Primary Prevention,
 Secondary Prevention
CTT 201020—26 trials
Included:
More vs. less statin
TNT46
IDEAL47
PROVE-IT48
A–Z117
SEARCH124
Statin vs. control (statin/dose,  
  percent LDL-C reduction)
4S47 S20–40, –36%
WOSCOPS72 P40, –22%
CARE130 P40, –29%
AFCAPS/TexCAPS17 L20-40, –24%
LIPID74 P40, –27%
GISSI-P86 P20, –9%
LIPS122 F40 BID, –27%
HPS16 S40, –38%
PROSPER38 P40, –27%
ALLHAT-LLT131 P40, –14%
ASCOT-LLA132 A10, –31%
ALERT133 F40, –20%
CARDS75 A10, –38%
ALLIANCE118—NA
4D85—A20, –27%
ASPEN119 A10, –34%
MEGA18 P10–20, –17%
JUPITER49 R20, –40%
GISSI-HF86 R10, –30%
AURORA84 R10, –38%
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14 In adults with CHD (including acute coronary syndromes, or a history of  
MI, stable or unstable angina, coronary revascularization), statin therapy 
reduced the RR for CVD events by approximately 21% per 1-mmol/L  
(38.7-mg/dL) LDL-C reduction. This relationship was similar for more 
intensive compared with less intensive statin therapy and for statin therapy 
compared with placebo/control.
H Secondary Prevention CTT 201020—26 trials—see above
15 In adults with CVD other than CHD (including stroke, TIA presumed to be of 
atherosclerotic origin, or peripheral arterial disease or revascularization), 
statin therapy reduced the RR for CVD events by approximately 19% per 
1-mmol/L (38.7-mg/dL) LDL-C reduction. This relationship was similar for 
more intensive compared with less intensive statin therapy and for statin 
therapy compared with placebo/control.
H Secondary Prevention CTT 201020—26 trials
16 In adults with diabetes and CHD or other CVD, moderate-dose statin therapy 
reduced CVD events by approximately 20% per 1-mmol/L (38.7-mg/dL) 
LDL-C reduction.
H Secondary Prevention  
  (diabetes subgroup 
included)
CTT 2008134—14 trials
17 In adults with and without CVD, statin therapy reduced CVD events in both  
men and women.
H Primary Prevention,
 Secondary Prevention
CTT 201020—26 trials
18 In adults with and without CVD, in trials comparing more* intensive with less 
intensive statin therapy, or statin therapy with placebo/control, there were 
no clinically important differences in the CVD risk reduction between the 
subgroups listed below:
•	Treated hypertension or all others
•	Systolic blood pressure <140, ≥140 to <160, and ≥160 mm Hg
•	Diastolic blood pressure <80, ≥80 to <90, and ≥90 mm Hg
•	Body mass index <25, ≥25 to <30, and ≥30 kg/m2
•	Current smoking and nonsmokers
•	GFR <60, 60 to <90, ≥90 mL/min per 1.73 m2)
•	Post-MI
•	Total cholesterol ≤5.2 (201 mg/dL), >5.2 to 6.5, >6.5 (251 mg/dL) mmol/L
•	Triglycerides ≤1.4 (124 mg/dL), >1.4 to 2.0, >2.0 (177 mg/dL) mmol/L
•	HDL-C ≤1.0 (39 mg/dL), >1.0 to ≤1.3, >1.3 (50 mg/dL) mmol/L
H Primary Prevention,
 Secondary Prevention
CTT 201020—26 trials
19 In more vs. less statin and statin vs. control trials combined, each 1-mmol/L 
(38.7-mg/dL) reduction in LDL-C resulted in approximately 22% reductions 
in CVD risk across baseline LDL-C levels [<2 mmol/L (77 mg/dL), ≥2 to 
<2.5 mmol/L (97 mg/dL), ≥2.5 to <3.0 mmol/L (116 mg/dL), ≥3.0 to 
<3.5 mmol/L (135 mg/dL), and ≥3.5 mmol/L, either untreated or on statin 
therapy]. In the statin vs. placebo/control trials, those with LDL-C <2 mmol/L 
may have experienced less benefit than those with higher LDL-C level.
M CTT 201020—26 trials
20 In adults, statins reduce the RR for CVD, CHD, and fatal CHD similarly in those 
with or without hypertension. This benefit applies across all levels of baseline 
systolic and diastolic blood pressure and in those with treated hypertension.
H Primary Prevention,
 Secondary Prevention
CTT 2010,20 Messerli AJC 2008135
21 In adults with and without CVD who received more intensive compared with 
less intensive statin therapy, or statin therapy compared with placebo/
control, the RR for first stroke was reduced by approximately 16% 
per 1-mmol/L (38.7-mg/dL) LDL-C reduction, primarily because of an 
approximately 21% reduction in the RR for ischemic stroke.
M to H Primary Prevention,
 Secondary Prevention
CTT 201020—26 trials
22 In adults with and without CHD/CVD who received more intensive compared 
with less intensive statin therapy, or statin therapy compared with 
placebo/control:
•	The RR for major coronary events was reduced by approximately 24%  
per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
•	The RR for nonfatal myocardial infarction was reduced by approximately  
27% per 1-mmol/L LDL-C reduction.
•	Total mortality was reduced by approximately 10% per 1-mmol/L  
 (38.7-mg/dL) LDL-C reduction, primarily because of a 16% reduction  
in the risk for cardiac death.
•	The risk for CVD mortality was reduced by approximately 14% per  
 1-mmol/L (38-mg/dL) LDL-C reduction, primarily because of a 16% 
reduction in the risk for cardiac death.
H Primary Prevention,
 Secondary Prevention
CTT 201020—26 trials
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23 In adults with CHD or acute coronary syndromes who received more  
intensive compared with less intensive statin therapy, the RR for  
coronary revascularization was reduced by approximately 34% per 
1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Secondary Prevention CTT 201020—5 trials
24 In adults with and without CVD who received statin therapy compared  
with placebo/control, the RR for coronary revascularization was  
reduced by approximately 24% per 1-mmol/L (38.7-mg/dL)  
LDL-C reduction.
H Primary Prevention,
 Secondary Prevention
CTT 201020—21 trials
25 In adults with and without CVD who received statin therapy, a larger  
absolute reduction in LDL-C (mmol/L or mg/dL) was associated with  
a greater reduction in the risk for CVD.
M Primary Prevention,
 Secondary Prevention
CTT2010,20 Kizer 2010136
26 In adults with and without CVD who received statin therapy, there was 
no variation in the relative reduction of CVD risk among the trials after 
adjustment for LDL-C reduction. Thus, LDL-C reduction appeared to  
account for the reduction in CVD risk.
M Primary Prevention,
 Secondary Prevention
CTT 201020
27 Consistent 23%–28% relative reductions in CVD risk per 39-mg/dL  
(1-mmol/L) reduction in LDL-C were observed after 1 year to beyond  
5 years of statin treatment.
H Secondary Prevention,
 Primary Prevention
CTT 2008,134 200550 CTT 201096
28 Statins reduce the RR for CVD similarly in primary- and  
secondary-prevention populations.
H Primary Prevention;
 Secondary Prevention
CTT 201020 CTT 2010  
 Web appendix50
29 In adults with diabetes (some of whom had CHD), statin therapy reduced  
the RR for CVD events by approximately 20% per 1-mmol/L  
(38.7-mg/dL) LDL-C reduction. This 1-mmol (20%) risk-reduction 
relationship was similar for more intensive compared with less intensive 
statin therapy and for statin therapy compared with placebo/control.
H Secondary Prevention  
  (includes diabetes 
subgroup)
Primary Prevention  
  in Individuals With 
Diabetes
CTT 201020 CTT 2008134
30 Adults with type 2, type 1, and no diabetes had similar RRRs in CVD per 
1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Primary Prevention  
  in Individuals With 
Diabetes
CTT 201020
31 In adults with diabetes without CVD, moderate-dose statin therapy,  
compared with placebo/control, reduced the RR for CVD events by 
approximately 27% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Primary Prevention in  
  Individuals With  
Diabetes
CTT 2008134—14 trials
32 In adults with diabetes, statin therapy reduced the RR for CVD by a  
similar magnitude for subgroups of diabetic men and women, <65 and  
≥65 years of age; treated hypertension; body mass index <25, >25 to  
<30, and ≥30; systolic blood pressure <160 and ≥160 mm Hg; diastolic 
blood pressure <90 and ≥90 mm Hg; current smokers and nonsmokers; 
estimated GFR <60, ≥60 to <90, and ≥90 mL/min/1.73 m2; and predicted 
annual risk for CVD <4.5%, >4.5% to <8.0%, and ≥8.0%. Whereas RRRs 
are similar across these subgroups, absolute risk reductions may differ  
for various subgroups.
H Primary Prevention  
  in Individuals With 
Diabetes
CTT 2008134—14 trials
33 In adults 40 to 75 years of age with diabetes and ≥1 risk factor, fixed 
moderate-dose statin therapy that achieved a mean LDL-C of 72 mg/dL 
reduced the RR for CVD by 37% (in this trial, LDL-C was reduced by  
46 mg/dL or 39%).
M Primary Prevention  
  in Individuals  
With Diabetes
CARDS75
34 In men and postmenopausal women 40 to 73 years of age without CHD/CVD, 
the majority of whom did not have diabetes and had baseline LDL-C levels 
<190 mg/dL, fixed low- to moderate-dose statin therapy that achieved a 
mean LDL-C of 115–127 mg/dL reduced the RR for CVD by 24%–25%, 
compared with placebo, with mean LDL-C levels of 153–156 mg/dL.  
(In these trials, LDL-C was reduced by 29–35 mg/dL and 19%–25% from 
baseline with a low- to moderate-dose statin.)
H Primary Prevention AFCAPS;17 MEGA18
35 In men ≥50 years and women ≥60 years of age without CHD/CVD with 
LDL <130 mg/dL and hs-CRP ≥2 mg/L, fixed intensive-dose statin that 
achieved a mean LDL-C of 53 mg/dL reduced the RR for CVD events by 44% 
compared with placebo, which had a mean LDL-C 110 mg/dL. In this trial, 
LDL-C was reduced by 53 mg/dL, or 49%.
M Primary Prevention JUPITER49
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36 In adults without CVD (some of whom had diabetes) who received more 
intensive or less intensive statin therapy, or statin therapy compared  
with placebo/control, the RR for CVD events was reduced by approximately 
25% per 1-mmol/L LDL-C reduction. This was similar to the CVD RRR 
observed in those with CHD or CVD.
H Primary Prevention CTT 201020
37 Statin therapy reduces CHD and stroke events in adults ≥40 years of age 
without CHD/CVD, and with a wide range of baseline LDL-C levels.
H Primary Prevention CTT 201020
JUPITER49
AFCAPS17
MEGA18
38 Statin therapy, with a range of LDL-C lowering, reduces all-cause mortality, 
compared with placebo, in primary-prevention clinical trials of adults who 
were in general ≥40 years of age and had at least 1 risk factor, and with a 
wide range of baseline LDL-C levels.
M Primary Prevention CTT 201020
39 There is insufficient evidence to determine the benefit of statins in primary 
prevention on all-cause mortality separately for women and men or with 
advancing age.
I Primary Prevention CTT 201020
40 In MEGA,18 AFCAPS,17 JUPITER,49 and CARDS,75 the 10-year NNTs to  
prevent 1 hard CVD event were 82, 56, 30, and 15, respectively.  
These reflect RRRs of 24%, 26%, 44%, and 37%, respectively, and  
placebo event rates for major CVD calculated at 10 years of 5.1%, 6.9%, 
7.6%, and 18%, respectively.
M Primary Prevention CTT 201020 appendix  
  individual trials—projected 
calculation
41 In adults without CVD (some of whom had diabetes) overall, who received 
statin therapy compared with placebo/control, the RR for CVD events was 
reduced by approximately 25% per 1-mmol/L LDL-C reduction. This was 
similar to the CVD RRR observed in those with CHD or CVD.
H Primary Prevention,
Primary Prevention  
  in Individuals With 
Diabetes
CTT 201020
42 Statin therapy, with a range of LDL-C lowering, reduces all-cause  
mortality by about 10%, compared with placebo, in primary-prevention 
clinical trials of adults who were ≥40 years of age and in general who  
had at least 1 risk factor, and with a wide range of baseline LDL-C levels.
M Primary Prevention,  
 efficacy
Cochrane,15 Ray,137 Brugts,138  
  Bukkapatnam,139 JUPITER49
 MEGA—women140
43 In adults with and without CVD, intensive- and moderate-dose statins  
do not increase the risk for death from noncardiovascular causes,  
regardless of baseline LDL-C. Statins do not increase (or decrease)  
the risk for incident cancer overall or cancer of any type, or the risk  
for cancer death.
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins
CTT 2010,20 Mills 2008,97  
Cochrane,15 Bonovas141
44 In adults with or without CVD, statin therapy is associated with an  
excess risk for incident diabetes.
•	Statin therapy was associated with 1 excess case of incident diabetes  
 per 1000 individuals treated for 1 year, compared with  
placebo/control, with little heterogeneity among 13 trials  
(including JUPITER49). Risk for diabetes was highest in older  
persons (NNH=1002 per year).
•	Statin therapy resulted in 5.4 fewer major CVD events per 1-mmol/L  
 LDL-C reduction per 1000 individuals treated for 1 year compared  
with placebo (NNT to benefit, 185 per year).
•	High-intensity statin therapy was associated with 2 excess cases of  
 incident diabetes per 1000 individuals treated for 1 year, compared  
with moderate-intensity statins (NNH=498 per year). High-intensity  
statin therapy resulted in 6.5 fewer major CVD events per 1000  
individuals treated for 1 year, compared with moderate-intensity statin 
therapy (NNT=155 per year). Rosuvastatin 20 mg was associated with 
3 excess cases of incident diabetes per 1000 individuals treated for  
1 year, compared with placebo (NNH=332 per year).
•	Rosuvastatin 20 mg resulted in 5.9 fewer major CVD events per  
 1000 individuals treated for 1 year, compared with placebo  
(NNT=169 per year).
M Primary Prevention,
 Secondary Prevention,
 Safety of Statins
Sattar 201081
Preiss,142 PROVE-IT,48 A–Z,117 TNT,46  
 IDEAL,47 SEARCH,124 JUPITER49
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45 In trials of high-intensity compared with moderate-intensity statins  
(clinical CVD), moderate-intensity statin compared with placebo  
(diabetes—primary prevention), high-intensity statin compared with  
placebo (secondary and primary prevention), or statin-niacin versus  
placebo, participants were:
•	Seen at visits that occurred at 4–13 weeks after randomization, and  
every 3–6 months thereafter.
•	Counseled on diet (IDEAL,47 AFCAPS,17 MEGA,18 PROVE-IT,48 SPARCL107)  
 and lifestyle (JUPITER49) at baseline and regularly thereafter or when  
LDL-C increased (JUPITER,49 CARDS75).
•	Assessed for adherence to study medication at every visit.
•	Assessed for adverse effects by history and laboratory measurements at  
every visit or every other visit.
•	Able to reduce the statin dose for adverse events so that atorvastatin  
 80 mg could be reduced to 40 mg (IDEAL47, PROVE-IT48) or pravastatin  
40 mg could be reduced to 20 mg (PROVE-IT48) or simvastatin reduced  
by 10 mg/d (HATS121).
•	Able to reduce the statin dose if LDL-C decreased to <39 mg/dL (1.0 mmol/L) 
 (per investigator discretion in IDEAL47) or reduce the statin dose if total 
cholesterol was <100 mg/dL on 2 successive visits (AFCAPS17) or reduce by 
10 mg simvastatin per day if LDL-C was <40 mg/d (HATS121), although they 
continued on study drug no matter how low the cholesterol in CARDS.75
•	Allowed to have their statin doses uptitrated or switched to more potent  
statin to further reduce
•	LDL-C (IDEAL47, CARDS75, AFCAPS17, MEGA18, PROVE-IT48—pravastatin  
to 80 mg) if LDL-C exceeded 125 mg/dL.
•	Given counseling on diet and/or glycemic control when LDL-C or  
triglyceride levels increased (CARDS75).
•	Had study medication discontinued for CK ≥10 × ULN with muscle  
 aches or weakness, or persistent ALT ≥3 × ULN on 2 consecutive tests 
(JUPITER49, CARDS75); the dose of atorvastatin or pravastatin could be 
halved for abnormal LFTs, CK elevations, or myalgias (PROVE-IT48).
H Statin Adherence Reflects review of TNT,46 IDEAL,47  
  PROVE-IT,48 CARDS,75 JUPITER,49 
SPARCL,107 MEGA,18 AFCAPS17 
baseline and main papers; these 
were statin trials that demonstrated 
significant CVD risk reduction (and 
were the basis of recommendations 
arising from CQ1 and CQ2) HATS121
46 Most RCTs of moderate-intensity statin therapy and all RCTs of high-intensity 
statin therapy excluded subjects with serious comorbidities and other 
conditions or concomitant drug therapy predisposing to adverse events  
from statin therapy (see Table 9).
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins,
 Safety of Nonstatins
RCTs included in CQ1, 2, and 3:
A–Z,117 ACCORD,14 AIM-HIGH,9  
  ASPEN,119 CARE,130 CDP,101 FIELD,115 
GREACE 120, HATS 121, HHS,111 HPS,16 
IDEAL,47 JUPITER,49  
LIPID,74 LIPS,122 LRC,113  
MIRACL,93 MUSHASHI-AMI,123 
PROVE-IT,48 SEAS,108 SHARP,109 
SPARCL,107 TNT46
47 In adults with and without CVD who received more intensive compared with 
less intensive statin therapy, or statin therapy compared with placebo/
control, overall the RR for first hemorrhagic stroke was not increased. 
Hemorrhagic stroke comprised 11% of total strokes in the more intensive/
statin group, compared with 8% in the less intensive/control groups.
M Primary Prevention,
 Secondary Prevention,
 Safety of Statins
CTT 201020
48 In adults with and without CVD, statin-treated individuals in clinical trials are 
not more likely to discontinue treatment than placebo-treated individuals.
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins
Cochrane—14 trials,15  
 CTT 201020
49 In adults with and without CVD in clinical trials, low- to moderate-dose statins 
do not increase the risk for myalgias or muscle pain.
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins
Cochrane—14 trials,15  
 CTT 201020
50 In adults selected for participation in clinical trials of statin therapy, 
rhabdomyolysis occurred rarely (<0.06% over a mean 4.8- to 5.1-year 
treatment period).
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins
CTT 201020
51 In adults with CHD, the rate of creatine kinase elevation ≥3 times ULN 
occurs infrequently and at a similar rate in those treated with intensive- or 
moderate-dose statin therapy.
H Primary Prevention,
 Secondary Prevention,
 Safety of Statins
Dale,98 CTT 201020
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52 In adults with CHD, although uncommon (<1.5% over 5 years), intensive statin 
therapy increases the risk for elevated hepatic transaminase (ALT and/or 
AST) levels ≥2–3 times ULN more than moderate-dose statin therapy. No 
cases of hepatic failure were reported.
H Primary Prevention,
 Safety of Statins
Dale,98 Cochrane,15 CTT 2010,20  
  TNT,46 IDEAL,47 PROVE-IT,48  
JUPITER49
53 Low- to moderate-dose statin therapy has similar rates of elevated hepatic 
transaminase levels as placebo/no statin treatment. In general, clinical 
trials tend to underestimate those likely to have side effects, often related to 
selection procedures.
H Primary Prevention,
 Safety of Statins
CTT 201020
54 With the exception of simvastatin 80 mg, intensive- and moderate-dose statins 
did not increase the risk for rhabdomyolysis.
L Safety of Statins CTT 2010,20 Cochrane,15 Mills97
55 In adults with CHD, CK elevation ≥3 times ULN occurs infrequently and at a 
similar rate in those treated with intensive- or moderate-dose statin therapy 
(0.02% [moderate-dose statin] to 0.1% [higher-dose statin]) over a 1- to 
5-year treatment period (RR 2.63, 95% CI 0.88–7.85).
H Secondary Prevention,
 Safety
Dale 200798
56 The Expert Panel did not find evidence that statins had an adverse effect on 
cognitive changes or risk of dementia.
I Safety of Statins Reviewed RCTs in CQ1, CQ2;  
  assessment of cognitive function  
only reported in HPS16
57 In men with CHD who are 30 to 64 years of age, immediate-release niacin 
(with an approximately 2-g dose):
•	Decreased total cholesterol by 10% and triglycerides by 27%.
•	Markedly increased the risk for adverse skin events (including flushing,  
pruritus, acanthosis nigricans, and other types of skin rash).
•	Increased the risk for other adverse events:Atrial fibrillation
•	Gastrointestinal events (including nausea, stomach pain, decreased  
appetite, and unexplained weight loss)
•	Gout
•	Elevated levels of uric acid, serum glutamic oxaloacetic transaminase,  
alkaline phosphatase, and glucose
•	Lipids, LFTs, uric acid, and glucose were monitored during up-titration  
and every 4–12 months thereafter.
L Secondary Prevention,
 Safety, Monotherapy,
 Safety, Efficacy
CDP101,143
58 In a trial in 67 adults with CHD and low HDL-C, slow-release niacin (at a mean 
2.4-g dose) plus low-dose simvastatin resulted in the following:
•	Low levels of LDL-C and raised levels of HDL-C.
•	Although not powered to detect a reduction in CVD events, the rate of  
major clinical events was 90% lower than that in the placebo group.
•	Slow-release niacin did not cause flushing in this trial.
•	The simvastatin-niacin group had increased ALT, CK, uric acid, and  
homocysteine.
•	Antioxidant vitamins diminished the beneficial effect of niacin on HDL-C.
•	Lipids, LFTs, uric acid, and glucose were monitored during up-titration  
and every 2–4 months thereafter.
L Secondary Prevention,
  Combination  
Treatment
HATS Investigators121
59 In adults 45 years of age and older with established CVD and low HDL-C  
(<40 mg/dL in men or <50 mg/dL in women), elevated triglycerides (150–400 
mg/dL), and LDL-C <180 mg/dL off statin, in whom the dose of simvastatin 
was adjusted, or ezetimibe was added, to maintain LDL-C in a range of  
40–80 mg/dL, extended-release niacin 1500–2000 mg/day plus simvastatin 
(9.5% also on ezetimibe 10 mg) compared with placebo (with 50 mg 
immediate-release niacin) plus simvastatin (21.5% also on ezetimibe 10 mg:
•	Improved the lipid profile without a further decrease in CVD events.  
 Specifically, it lowered LDL-C levels an additional 6%, increased HDL-C by 
an additional 14%, reduced triglycerides by an additional 23%, lowered 
apolipoprotein B by an additional 10%, and reduced lipoprotein(a) by an 
additional 19%.
•	There were similar rates of CVD events in subgroups by age, sex, or  
 diabetes, metabolic syndrome, or previous myocardial infarction status, 
as well as similar rates of adverse events, including liver function 
abnormalities, muscle symptoms, and rhabdomyolysis.
•	Lipids, LFTs, uric acid, and glucose were monitored during up-titration  
and every 3–12 months thereafter.
M Secondary Prevention,
  Combination  
Treatment
AIM-HIGH Investigators9
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ES No. Evidence Statement
Level of 
Evidence
Recommendation(s)/
Section References
60 In men 35–59 years of age without CHD, hypertension, diabetes, or 
obesity and with LDL-C ≥175 mg/dL and triglycerides <300 mg/dL, 
cholestyramine:
•	Reduced LDL-C by 13%, with minimal changes in  
triglycerides or HDL-C levels.
•	Reduced the RR for CHD events by 19%.
•	Increased the risk for adverse gastrointestinal effects, including  
constipation, heartburn, abdominal pain, belching, bloating, gas, nausea.
•	Adherence was only modest.
L Primary Prevention,
 Safety, Efficacy
LRC113
61 Insufficient data to evaluate the efficacy and safety of ezetimibe  
monotherapy.
I Efficacy, Safety,
 Nonstatin
62 Insufficient data to evaluate the additional efficacy and safety of ezetimibe  
in combination with a statin compared with a statin alone.
I Safety, Efficacy,
  Combination  
Treatment
63 In adults 45–85 years of age with mild to moderate aortic stenosis and  
without CVD or diabetes, simvastatin 40 mg coadministered with  
ezetimibe 10 mg, compared with placebo:
•	Decreased LDL-C by an average of 50%.
•	Reduced the RR for CVD events by 22% over 4.35 years of treatment.
•	Increased the risk for elevated hepatic transaminases.
L Safety, Efficacy,
  Combination  
Treatment
SEAS108
64 In adults ≥40 years of age with CKD, of whom 33% were receiving dialysis 
(peritoneal or hemodialysis), ezetimibe 10 mg coadministered with 
simvastatin 20 mg, compared with placebo:
•	Lowered LDL-C by 37 mg/dL (33%) in those who were not receiving  
dialysis and by 23% in those who were receiving dialysis.
•	Reduced the risk for CVD events by 17% overall and 21% in those  
without CVD.
•	Reduced the risk for CVD events by 22% in those who were not  
receiving dialysis.
•	Did not reduce CVD events in those with CVD or in those 
receiving  hemodialysis.
•	Modestly increased the risk for muscle symptoms requiring  
discontinuation of treatment (1.1% vs. 0.6% with P=0.02).
•	Did not increase the risk for elevated hepatic transaminases, cancer,  
hemorrhagic stroke, or noncardiovascular mortality.
L Safety, Efficacy,
  Combination  
Treatment, CKD
SHARP109
65 Ezetimibe coadministered with simvastatin does not appear to increase  
the risk for cancer compared with placebo.
L Safety, 
  Combination  
Treatment
SHARP109
66 In adults 50–75 years of age with diabetes—with total cholesterol  
<250 mg/dL, and total cholesterol/HDL ratio ≥4.0 or triglycerides  
<450 mg/dL—fenofibrate, compared with placebo:
•	Modestly reduced LDL-C, minimally increased HDL-C, and  
substantially reduced triglycerides.
•	In those without clinical CVD, reduced the risk for CHD/CVD events.
•	In those with clinical CVD, did not reduce the risk for CHD/CVD events.
•	Was no different than placebo for myositis or rhabdomyolysis, CK or ALT  
elevations, renal disease requiring hemodialysis, or cancer.
•	Was associated with higher rates of pancreatitis and pulmonary embolism, 
 and increased creatinine levels on average by 0.113–0.136 mg/dL  
(10–12 mmol/L).
L Safety,
  Efficacy, Nonstatin 
Treatment
FIELD115
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67 In adults 40–79 years of age with diabetes, CVD, and/or CVD risk factors,  
with LDL-C 60–180 mg/dL, HDL-C <55 mg/dL in women and black 
individuals, HDL-C <50 mg/dL for all others, and triglycerides <750 mg/dL 
on no medication or <400 mg/dL on medication:
•	Fenofibrate added to simvastatin did not additionally reduce LDL-C,  
 minimally increased HDL-C (1 mg/dL or 2%), and moderately reduced 
triglycerides (23 mg/dL or 14%), compared with simvastatin therapy, 
which had on-treatment mean LDL-C of 80 mg/dL, HDL-C of 40.5 mg/dL, 
and triglycerides of 170 mg/dL.
•	In the trial overall, and in those without and with clinical CVD,  
 fenofibrate-simvastatin did not reduce the risk for CVD events  
compared with simvastatin alone.
•	Those with triglycerides ≥204 mg/dL and HDL-C ≤40 mg/dL may  
 have experienced a reduction in CVD events from fenofibrate-simvastatin, 
compared with simvastatin alone.
•	Fenofibrate-simvastatin had similar rates as simvastatin alone for  
 myopathy, myositis, or rhabdomyolysis; CK or ALT elevations, renal disease 
requiring hemodialysis; cancer death; or pulmonary embolism/thrombosis.
•	Fenofibrate-simvastatin was more likely to increase ALT >5 times ULN  
and to increase creatinine level.
•	CVD event rates were higher in women with well-controlled diabetes  
who received fenofibrate-simvastatin compared with simvastatin alone.
M Safety, Efficacy,
 Nonstatin Treatment
ACCORD14
68 In men 40–55 years of age without CHD or CHF and non–HDL-C  
≥200 mg/dL, gemfibrozil:
•	Reduced LDL-C by 10% and triglycerides by 43%, and increased  
HDL-C by 10%.
•	Reduced the RR for CHD by 37%, compared with placebo.
•	Increased skin cancer, increased gastrointestinal surgery, and increased  
 severe upper gastrointestinal symptoms, especially in first year.  
There was no difference in diarrhea, constipation, nausea, or vomiting.  
Total mortality was not reported.
M Safety, Efficacy,
 Nonstatin Treatment
Helsinki Heart Study111
69 In men with CHD who were <74 years of age with HDL-C ≤40 mg/dL and LDL-C 
≤140 mg/dL, and triglycerides ≤300 mg/dL, gemfibrozil, compared with placebo:
•	Did not reduce LDL-C, but did reduce triglycerides by 31% and increase  
HDL-C by 6%.
•	Reduced the RR for CVD by 24%.
M Efficacy,
 Nonstatin Treatment
VA-HIT114
70 In Japanese men who were 40–75 years of age and postmenopausal  
women ≤75 years of age with and without CHD and LDL-C ≥170 mg/dL, 
EPA 1800 mg added to statin therapy:
•	Did not reduce LDL-C and modestly reduced triglycerides (5%), compared  
with statin therapy alone.
•	Reduced the risk for CHD events (including revascularization and unstable  
angina) by 19%, compared with statin therapy alone.
•	Caused a similar magnitude of risk reduction in primary- and  
 secondary-prevention populations, but the study was insufficiently 
powered to evaluate these populations separately.
•	Increased the risk for gastrointestinal disturbance, skin abnormalities,  
hemorrhage, and abnormal serum glutamic oxaloacetic transaminase.
M Efficacy, Safety,
 Combination Treatment
JELIS110
71 In individuals with NYHA Classes II–IV systolic or ischemic heart failure, 
initiation of a statin did not change the absolute or RR for CVD  
compared with placebo.
M Efficacy, Selected  
 Population Subgroups
CORONA85 from CQ1
72 In individuals receiving maintenance hemodialysis, initiation of a statin  
did not change the relative or absolute risk for CVD compared with placebo.
M Efficacy,
  Selected Population 
Subgroups
4D87 and AURORA84 CQ1 & CQ2,  
 SHARP109—HD subgroup
73 In men and women of mean age 58 to 68 years with aortic stenosis,  
treatment with statin or statin plus ezetimibe for a mean of 2.1–4.4 years 
resulted in a reduction in LDL-C of 50%–55% (67–73 mg/dL) from a 
baseline LDL-C of 123–140 mg/dL and did not alter the progression of aortic 
stenosis as assessed by change in valve area, peak aortic valve jet velocity, 
peak or mean aortic valve gradient, or need for aortic valve surgery.
H Aortic Stenosis,
 Combination Treatment
Parolari144
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74 Women who were pregnant or nursing were excluded from statin,  
fenofibrate, niacin-statin, and ezetimibe-statin RCTs.
Only men were enrolled in RCTs of niacin, BAS, and gemfibrozil.
H Primary Prevention,
 Secondary Prevention
All RCTs CQ1, CQ2, and CQ3
75 Only individuals with primary hypercholesterolemia were included in RCTs. H Primary Prevention,
 Secondary Prevention
AFCAPS17
JUPITER49
JELIS110
HATS121
FIELD115
ACCORD14
MEGA18
76 In the 3 exclusively primary-prevention RCTs, low-, moderate-, and  
high-intensity statin therapy reduced the risk for ASCVD when LDL-C  
levels were approximately 70–130 mg/dL, 130–190 mg/dL, and  
160–200 mg/dL.
H Primary Prevention JUPITER49
MEGA18
AFCAPS17
77 Lipids, liver function, uric acid, and glucose tests were obtained at baseline, 
during up-titration, and every 2–12 months thereafter.
H Secondary Prevention CDP101 (fair) 4–12 months;
 HATS121 (good) 2–4 months;
 AIM-HIGH9 (good) 3–12 months
78 Immediate- and extended-release niacin increase cutaneous adverse effects. M Secondary Prevention CDP,101 AIM-HIGH9 (not  
 HATS121—Slo-Niacin)
79 When used as monotherapy or with a statin, niacin increases:
•	Hepatic function tests.
•	Hyperglycemia.
•	Gastrointestinal adverse effects.
•	Gout or increased uric acid.
H
M
M
M
Secondary Prevention,
 Safety
(CDP,101 HATS,121 AIM-HIGH9)
(CDP,101 AIM-HIGH9—niacin dose  
 reduced or discontinued)
(CDP,101 AIM-HIGH9—niacin dose  
 reduced or discontinued)
Gout (CDP101)
Increased uric acid (HATS121)
80 Niacin increases the incidence of atrial fibrillation and weight loss. L Secondary Prevention,
 Safety
CDP101 (atrial fibrillation not reported  
 in AIM-HIGH9 or HATS121)
ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, bile acid sequestrant; BID, twice daily; CHD, coronary heart disease; CHF, 
congestive heart failure; CK, creatine kinase; CKD, chronic kidney disease; CVD, cardiovascular disease; EPA, eicosapentaenoic acid; ES, evidence statement; GFR, 
glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LFT, liver function test; MI, myocardial infarction; 
NNH, number needed to harm; NNT, number needed to treat; NYHA, New York Heart Association; RCT, randomized controlled trial; RR, relative risk; RRR, relative risk 
reduction; TIA, transient ischemic attack; and ULN, upper limit of normal.
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Appendix 5. Expanded Discussion of What’s New in the Guideline
Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups
•	The 2013 guideline focuses on treatment of blood cholesterol to reduce ASCVD risk. Each Expert Panel was limited in the number of CQs it could choose.  
 When the CQs from the Risk Assessment and Lifestyle Work Groups were combined with the 3 Cholesterol Panel CQs, there were 8 CQs in total that were 
systematically reviewed. All 3 CQs of the Cholesterol Panel evaluated evidence from RCTs with ASCVD outcomes. CQ1 and CQ2 evaluated the evidence for LDL-C 
and non–HDL-C goals in secondary and primary prevention. CQ3 was a comprehensive evaluation of the reduction in ASCVD events and safety for each of the 
cholesterol-lowering drugs available in the United States.
•	The systematic review of evidence from the highest-quality RCTs with ASCVD outcomes identified strong evidence to indicate who should get which therapy  
at what intensity.
•	The statin RCTs provided the most extensive evidence for the greatest magnitude of ASCVD event reduction, with the best margin of safety.
•	Four	statin	benefit	groups were identified, in which the potential for an ASCVD risk-reduction benefit clearly exceeds the potential for adverse effects in:
1. Individuals with clinical ASCVD
2. Individuals with primary elevations of LDL-C ≥190 mg/dL
3. Individuals 40–75 years of age with diabetes but without clinical ASCVD and LDL-C 70–189 mg/dL
4.  Individuals 40–75 years of age without diabetes or clinical ASCVD with LDL-C 70–189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.  
 This requires a clinician-patient discussion.
•	Because few trials have been performed with nonstatin cholesterol-lowering drugs in the statin era, and those that have been performed were unable to  
 demonstrate significant additional ASCVD event reductions in the RCT populations studied, there was less evidence to support the use of nonstatin drugs for 
ASCVD prevention.
•	It is difficult to determine how observational data could override the conclusions from the extensive body of evidence from the statin RCTs and the paucity  
 of evidence from nonstatin RCTs. Inherent biases of observational data are well understood and include biases in the decisions on whom to treat and who is 
adherent to therapy, as well as multiple measurement biases, including verification of statin use, type and dose of statin used, consistency of use over time, and 
outcome ascertainment. All of these problems are addressed in intent-to-treat analyses of RCTs, which is why the FDA requires well-designed RCTs to determine 
drug efficacy for ASCVD event reduction and common adverse effects.
•	Other approaches to treatment of blood cholesterol have been advocated, including:
A.  Treat to target—This strategy has been the most widely used in the past 15 years, but there are 3 problems with this approach. First, current clinical trial  
 data do not indicate what the target should be. Second, we do not know the magnitude of additional ASCVD risk reduction that would be achieved with one 
target lower than another. Third, this strategy does not take into account potential adverse effects from statin monotherapy or from multidrug therapy that 
might be needed to achieve a specific goal. Thus, in the absence of these data, this approach is less useful than it appears (Section 3). It is possible that 
future clinical trials may provide information warranting reconsideration of this strategy.
B.  Lowest is best—This approach was not taken because it does not consider the potential adverse effects of multidrug therapy with an unknown magnitude  
of ASCVD event reduction. Ongoing RCTs of new LDL-C–lowering drugs in the setting of maximal statin therapy may address this question.
C.  Treat level of ASCVD risk—A modified version of this approach was taken, which considers both the ASCVD risk-reduction benefits and the adverse  
 effects of statin treatment on the basis of an extensive body of RCT evidence to determine the 4 statin benefit groups. By focusing treatment on the 4 statin 
benefit groups, the approach is practical and simpler to implement than the past strategies. There are also important exceptions for routine initiation of statin 
treatment for individuals requiring hemodialysis or with NYHA class II to IV heart failure.
D.  Lifetime risk—Treatment strategies based on lifetime ASCVD risk are problematic because of the lack of data on the long-term follow-up of RCTs >15 years, 
the safety and ASCVD event reduction when statins are used for periods >10 years, and treatment of individuals <40 years of age.
A New Perspective on LDL-C and/or Non–HDL-C Goals
•	The difficulty of giving up the treat-to-goal paradigm was deliberated extensively over a 3-year period. Many clinicians use targets such as LDL-C <70 mg/dL  
 and LDL-C <100 mg/dL for secondary and primary ASCVD prevention (non–HDL-C targets are 30 mg/dL higher). However, the RCT evidence clearly shows 
that ASCVD events are reduced by using the maximum-tolerated statin intensity in those groups shown to benefit. After a comprehensive review, no RCTs 
were identified that titrated drug therapy to specific LDL-C or non–HDL-C goals to improve ASCVD outcomes. However, one RCT was identified that showed no 
additional ASCVD event reduction from the addition of nonstatin therapy to further treat non–HDL-C levels once an LDL-C goal was reached. In AIM-HIGH,9 the 
additional reduction in non–HDL-C levels [as well as additional reductions in Apo B, Lp(a), and triglycerides in addition to HDL-C increases] with niacin therapy 
DID	NOT further reduce ASCVD risk in individuals treated to LDL-C levels of 40–80 mg/dL.
•	Use of LDL-C targets may result in under treatment with evidence-based statin therapy or overtreatment with nonstatin drugs that have not been shown to  
 reduce ASCVD events in RCTs (even though the drug may additionally lower LDL-C and/or non–HDL-C). Implications of treating to an LDL-C goal may mean 
that a suboptimal intensity of statin is used because the goal has been achieved, or that adding a nonstatin therapy to achieve a specific target results in down-
titration of the evidence-based intensity of statin for safety reasons. However, when RCT evidence is available that a nonstatin therapy further reduces ASCVD 
events when added to statin therapy, the nonstatin therapy may be considered.
•	Some examples comparing a strategy based on the 4 statin benefit groups to a strategy using LDL-C/non–HDL-C targets:
A.  Secondary prevention—Evidence supports high-intensity statin therapy for this group to maximally lower LDL-C. It does not support the use of an LDL-C  
 target. For example, if a secondary-prevention patient achieves an LDL-C of 78 mg/dL on a dose of 80 mg of atorvastatin, he/she is receiving evidence-
based therapy. As of yet, there are no data to show that adding nonstatin drug(s) to high-intensity statin therapy will provide incremental ASCVD risk-
reduction benefit with an acceptable margin of safety. Indeed, AIM-HIGH9 demonstrated the futility of adding niacin in individuals with low HDL-C and high 
triglycerides, and ACCORD14 demonstrated the futility of adding fenofibrate in persons with diabetes. Although an ACCORD subgroup analysis of those with 
high triglycerides and low HDL-C levels suggested that fenofibrate may reduce ASCVD events in patients with diabetes, this is hypothesis generating and 
needs further testing in comparison to the evidence-based use of a high-intensity statin. In addition, not having a goal of <70 mg/dL for LDL-C means that the 
patient who is adhering to optimal lifestyle management and receiving a high-intensity statin avoids additional, non–evidence-based therapy just because his/
her LDL-C is higher than an arbitrary cutpoint. Indeed, the LDL-C goal approach can make this patient unnecessarily feel like a failure.
(Continued)
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Appendix 5. Continued
B.  Familial hypercholesterolemia with LDL-C ≥190 mg/dL—In many cases, individuals with familial hypercholesterolemia are unable to achieve an LDL-C  
 goal <100 mg/dL. For example, an individual with familial hypercholesterolemia may achieve an LDL-C of only 120 mg/dL despite use of 3 cholesterol-
lowering drugs. Although this patient may have fallen short of the 100-mg/dL goal, he/she has decreased his/her LDL-C by >50% (starting from an untreated 
LDL-C level of ~325–400 mg/dL). These patients are not treatment failures, as observational data has shown significant reductions in ASCVD events without 
achieving specific LDL-C targets. This is an area where observational data supports the recommended approach.
C.  Type 2 diabetes—For those 40–75 years of age with risk factors, the potential benefits of LDL-C lowering with a high-intensity statin are substantial.  
 Because those with diabetes often have lower LDL-C levels than those without diabetes, “goal”-directed therapy often encourages use of a lower statin dose 
than is supported by the RCTs, and nonstatin drugs may be added to address low HDL-C or high triglycerides, for which RCT evidence of an ASCVD event 
reduction is lacking. Giving a maximally tolerated statin intensity should receive primary emphasis because it most accurately reflects the data that statins 
reduce the relative risk of ASCVD events similarly in individuals with and without diabetes, and in primary and secondary prevention in those with diabetes, 
along with evidence that high-intensity statins reduce ASCVD events more than moderate-intensity statins.
D.  Estimated 10-year ASCVD risk ≥7.5%—Data have shown that statins used for primary prevention have substantial ASCVD risk-reduction benefits across  
 the range of LDL-C levels of 70–189 mg/dL. Moreover, the Cochrane meta-analysis,15 as well as a meta-analysis by the Cholesterol Treatment Trialists,13 
confirms that primary prevention with statins reduces total mortality as well as nonfatal ASCVD events.
•	RCTs are used to identify those who are unlikely to benefit from initiation of statin therapy despite being at high ASCVD risk, such as those with higher NYHA  
classes of heart failure or those on hemodialysis.
Global Risk Assessment for Primary Prevention
•	Use of the new Pooled Cohort Equations is recommended to estimate 10-year ASCVD risk in both white and black men and women who do not have  
clinical ASCVD.
•	By more accurately identifying higher-risk individuals for statin therapy, the guideline focuses statin therapy on those most likely to benefit.
•	It also indicates, on the basis of RCT data, those high-risk groups that might not benefit. The Expert Panel emphasizes that the guideline is “patient centered” in  
 primary prevention. It is recommended that the potential for an ASCVD risk-reduction benefits, adverse effects, and drug–drug interactions, along with patient 
preferences, must be considered before statins are initiated for the primary prevention of ASCVD. Other factors such as LDL-C ≥160 mg/dL may also be considered. 
This gives clinicians and patients the opportunity for input into treatment decisions rather than a simplistic “one-treatment-fits-all” approach to drug therapy.
•	These guidelines are not a replacement for clinical judgment; they are meant to guide and inform decision making.
•	Some worry that a person 70 years of age without other risk factors will receive statin treatment on the basis of age alone. The estimated 10-year risk is still  
 ≥7.5%, a risk threshold for which a reduction in ASCVD risk events has been demonstrated in RCTs. Most ASCVD events occur after age 70 years, giving 
individuals ≥70 years of age the greatest potential for absolute risk reduction.
•	Some have proposed using selected inclusion criteria from RCTs to determine the threshold for statin initiation. However, the Cholesterol Treatment Trialists  
 individual-level meta-analysis showed that statin therapy reduces ASCVD events regardless of categorical risk factors in both primary and secondary 
prevention. Therefore, the rationale for using fixed cutpoints to determine whether statin therapy should be initiated is refuted by a consideration of the total 
body of evidence from RCTs.
•	In addition, a trial-based strategy identifies those at increased ASCVD risk less accurately than does a strategy based on an assessment of global ASCVD risk.  
 This selective use of inclusion criteria excludes well-established risk factors, such as smoking and advancing age (the strongest risk factor because it represents 
cumulative risk factor exposure).
•	The poor discrimination of RCT inclusion criteria for identifying those at increased 10-year ASCVD risk is shown by a calculation performed by the Risk  
 Assessment Work Group using nationally representative data from NHANES. Use of the RCT inclusion criteria (from RCTs that found a reduction in ASCVD events 
to guide initiation of statin therapy) would result in the treatment of 16% of individuals with <2.5% estimated 10-year ASCVD risk and 45% of those with 2.5% to 
<5% estimated 10-year ASCVD risk (many would say inappropriately), whereas 38% of those with ≥7.5% 10-year ASCVD risk would not have been identified as 
candidates for statin therapy.
Safety
•	RCTs are used to identify important safety considerations in individuals receiving treatment of blood cholesterol to reduce ASCVD risk and to determine statin  
adverse effects to facilitate understanding of the net benefit from statin therapy.
•	Safety issues that are uncommon or unlikely to be seen in the populations studied in RCTs require more than analyses of single RCTs. This limitation was  
overcome, in part, by considering high-quality systematic reviews and meta-analyses of statin RCTs.
•	Expert guidance is provided on management of statin-associated adverse effects, including muscle symptoms.
•	This guideline emphasizes the importance of using additional sources of information on safety, including FDA reports, manufacturers’ prescribing information,  
and pharmacists, to aid in the safe use of cholesterol-lowering drug therapy.
Role of Biomarkers and Noninvasive Tests
•	There is a concern about other factors that may indicate elevated ASCVD risk but were not included in the Pooled Cohort Equations for predicting 10-year  
ASCVD risk.
•	The Risk Assessment Work Group has performed an updated systematic review of nontraditional risk factors, such as CAC, and has included recommendations  
to consider their use to the extent that the evidence allows.
•	In selected individuals who are not in 1 of the 4 statin benefit groups, and for whom a decision to initiate statin therapy is otherwise unclear, additional factors  
may be considered to inform treatment decision making.
•	These factors include primary LDL-C ≥160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years  
 of age in a first-degree male relative or <65 years of age in a first-degree female relative; high-sensitivity C-reactive protein ≥2 mg/L; CAC score ≥300 
Agatston units or ≥75th percentile for age, sex, and ethnicity; ankle-brachial index <0.9; and elevated lifetime risk of ASCVD. Additional factors may be 
identified in the future.
(Continued)
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Appendix 5. Continued
Future Updates to the Blood Cholesterol Guideline
•	This guideline focuses on treatments proven to reduce ASCVD events. It is not and was never intended to be a comprehensive approach to lipid management.
•	Using RCT evidence assessed for quality provides a strong foundation for treatment of blood cholesterol to reduce ASCVD risk that can be used now. There are  
 many clinical questions for which there is an absence of RCT data available to develop high-quality, evidence-based recommendations. For these questions, 
expert opinion may be helpful to clinicians and could be developed in the next iteration of the guideline.
•	CQs for future guidelines could examine:
1. the treatment of hypertriglyceridemia;
2. the use of non–HDL-C in treatment decision making;
3. whether on-treatment markers such as Apo B, Lp(a), or LDL particles are useful for guiding treatment decisions;
4. the best approaches to using noninvasive imaging for refining risk estimates to guide treatment decisions;
5. how lifetime ASCVD risk should be used to inform treatment decisions and the optimal age for initiating statin therapy to reduce lifetime risk of ASCVD;
6. subgroups of individuals with heart failure or undergoing hemodialysis who might benefit from statin therapy;
7. long-term effects of statin-associated new-onset diabetes and management;
8. efficacy and safety of statins in patient groups excluded from RCTs to date (eg, those who are HIV positive or have received a solid organ transplant); and
9. role of pharmacogenetic testing.
*For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
AIM-HIGH indicates Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes; ACCORD, 
Action to Control Cardiovascular Risk in Diabetes; Apo B, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CQ, critical 
question; FDA, US Food and Drug Administration; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); 
NHANES, National Health and Nutrition Examination Survey; and RCTs, randomized controlled trials.
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Correction
S46
In the article by Stone et al, “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol 
to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines,” which published 
online November 12, 2013, and appears in the supplement to the June 24, 2014, issue of the journal 
(Circulation. 2014;129[suppl 2]:S1–S45), several corrections were needed.
These corrections have been made to the print version and to the current online version of the article, 
which is available at http://circ.ahajournals.org/lookup/doi/10.1161/01.cir.0000437738.63853.7a.
1.  On the title page, the American Academy of Physician Assistants has been added as an endors-
ing organization.
2.  On the title page, the first footnote paragraph now reads “This document was approved by 
the American College of Cardiology Board of Trustees and the American Heart Association 
Science Advisory and Coordinating Committee in November 2013. The Academy of Nutrition 
and Dietetics affirms the value of this guideline.” The footnote previously did not refer to the 
Academy of Nutrition and Dietetics.
3.  On the title page, Robert A. Guyton, MD, FACC, was listed as a member of the ACC/AHA 
Task Force. His name has been removed from the list of Task Force members.
4.  Throughout the article, mathematical symbols have been changed as follows:
•  “triglycerides >500 mg/dL” has been changed to “triglycerides ≥500 mg/dL”
• “ALT >3 X ULN” has been changed to “ALT ≥3 times ULN”
• “non−HDL-C level >220 mg/dL” has been changed to “non−HDL-C level ≥220 mg/dL”
•  “high-sensitivity C-reactive protein >2 mg/L” has been changed to “high-sensitivity 
C-reactive protein ≥2 mg/L”
5.  Throughout the article, callouts to the “Full Panel Report Supplement” have been hyperlinked 
to the report.
6.  Throughout the article, the Web-based calculator links have been updated to:
•  http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/2013-Prevention-Guideline-Tools.aspx and
•  http://my.americanheart.org/cvriskcalculator
7.  In Section 1.2, the last paragraph, the American Academy of Physician Assistants has been 
added as an endorsing organization.
8.  In Section 2, Table 3, titled “Expanded Discussion of What’s New in the Guideline,” is now 
Appendix 5. The respective callouts in the text have been updated.
9.  In Section 2, a new Table 3 has been inserted. Its updated title is, “Summary of Key 
Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults.” 
The following callout sentence has been added to the text: “A summary of the major recom-
mendations for the treatment of cholesterol to reduce ASCVD risk is provided in Table 3.”
10.  In Section 2.1, end of the first paragraph, the following sentence has been added: “Drug ther-
apy for lifestyle-related risk factors such as hypertension is often needed and smoking should 
be avoided.”
11.  In Section 2.2,
•  second paragraph, the second sentence read, “…or 4) without clinical ASCVD or diabetes 
with LDL-C 70 to 189 mg/dL and estimated 10-year ASCVD risk >7.5%....” It has been 
changed to read, “…and 4) primary prevention in individuals without diabetes and with esti-
mated 10-year ASCVD risk ≥7.5%, 40 to 75 years of age who have LDL-C 70 to 189 mg/dL.”
•  second paragraph, the following text has been added to the end of the paragraph: 
“Moderate evidence supports the use of statins for primary prevention in individuals with 
5% to <7.5% 10-year ASCVD risk, 40 to 75 years of age with LDL-C 70 to 189 mg/dL. 
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Selected individuals with <5% 10-year ASCVD risk, or <40 or >75 years of age may also 
benefit from statin therapy. Clinicians and patients should engage in a discussion of the 
potential for ASCVD risk-reduction benefits, adverse effects, drug−drug interactions, and 
consider patient preferences for treatment. This discussion also provides the opportunity 
to re-emphasize healthy-lifestyle habits and address other risk factors.”
•  penultimate paragraph, the following text has been added to the end of the paragraph: 
“In primary prevention, additional factors may influence ASCVD risk in those for whom 
a risk-based decision is unclear. These include a primary LDL-C ≥160 mg/dL or other 
evidence of genetic hyperlipidemias, family history of premature ASCVD with onset <55 
years of age in a first-degree male relative or <65 years of age in a first-degree female 
relative, high-sensitivity C-reactive protein ≥2 mg/L, coronary artery calcium score ≥300 
Agatston units or ≥75th percentile for age, sex, and ethnicity (for additional information, 
see http://www.mesa-nhlbi.org/CACReference.aspx), ankle-brachial index <0.9, and ele-
vated lifetime risk of ASCVD.”
12.  In Section 3.1, the third bullet read, “…to lower LDL-C.” It has been changed to read, “…to 
reduce ASCVD risk.”
13.  In Table 4, in the “Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/
dL” section, recommendation 4, the Class IIb level of evidence recommendation color has 
been changed from yellow to orange.
14.  In Section 4.5, the first paragraph, the last sentence, “…or whose LDL-C <70 mg/dL…” has 
been added so the sentence now reads, “In persons with diabetes who are <40 years of age or 
>75 years of age, or whose LDL-C <70 mg/dL, statin therapy…”
15.  In Section 4.6, the second paragraph, in the first and the penultimate sentences, the LDL-C 
level, which was >70 mg/dL, has been changed to ≥70 mg/dL.
16.  Figure 2 has been edited and clarified to more closely align with published recommendations. 
•  The 3 center diamonds have been colored green to correspond with Class I recommendations.
•  The top white box has been edited to read “Heart-healthy lifestyle habits are the founda-
tion of ASCVD prevention (See 2013 AHA/ACC Lifestyle Management Guideline).”
•  In the second white box on the left, “Age >21 y…” has been changed to “Age ≥21 y….”
•  A second green box has been added under the 3 gray boxes on the left that says, “Regularly 
monitor adherence to lifestyle and drug therapy with lipid and safety assessments (See Fig 5).”
• In the bottom half of the figure, stemming from the third diamond, “Diabetes”:
–  On the left side of the figure, a white box has been added that reads, “DM age <40 or >75 
or LDL-C <70 mg/dL.”
–  Under the diamond, a green Primary Prevention box has been added with 4 boxes breaking 
off to indicate categories of ASCVD risk.
–  An orange box has been added regarding additional factors under the boxes indicating cat-
egories of ASCVD risk.
– A yellow Clinician-Patient Discussion box has been added.
–  Two gray boxes have been added on the right indicating the decision on whether or not 
to add statin therapy.
• The footnotes have been modified according to updates in the figure.
17.  In Section 4.6, the last paragraph, reference 11 has been cited as follows: “For an individual 
<40 years of age, the 10-year horizon might not be optimal for predicting lifetime risk of 
ASCVD (see “2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk”).11”
18.  In Table 9, for the subheading “Safety of Fibrates,” the following footnote has been added to 
recommendation 3, second bullet: “*Consult the manufacturer’s prescribing information as 
there are several forms of fenofibrate available.”
19.  In Section 10, under the list “Four Statin Benefit Groups,” the following has been added to No. 
4: “This requires a clinician-patient discussion.”
20.  After the references, “Key Words” have been added: “AHA Scientific Statements ◼ cardio-
vascular disease ◼ cholesterol ◼ hydroxymethylglutaryl-CoA reductase inhibitors/statins ◼ 
primary prevention ◼ secondary prevention ◼ diabetes mellitus ◼ drug therapy ◼ risk assess-
ment ◼ risk reduction behavior ◼ patient compliance ◼ hypercholesterolemia ◼ lipids ◼ bio-
markers, pharmacological.”
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21.  In Appendix 1, the information for Susan T. Shero has been added.
Panel Member Employment Consultant Speaker’s  
Bureau
Ownership/ 
Partnership/ 
Principal
Personal 
Research
Expert  
Witness
Susan T. 
Shero
Ex-Officio
NHLBI—Public  
Health Advisor
2008–2012:
None
2013:
None
2008–2012:
None
2013:
None
2008–2012:
None
2013:
None
2008–2012:
None
2013:
None
2008–2012:
None
2013:
None
22.  In Appendix 2,
•  For Robert S. Rosenson, LipoScience was added to the Ownership/Partnership/Principal 
column.
•  The following has been added to the footnote: “This table represents the relationships 
of reviewers with industry and other entities that were self-disclosed at the time of peer 
review. It does not necessarily reflect relationships with industry at the time of publica-
tion. To review the NHLBI and ACC/AHA’s current comprehensive policies for managing 
relationships with industry and other entities, please refer to http://www.nhlbi.nih.gov/
guidelines/cvd_adult/coi-rwi_policy.htm and http://www.cardiosource.org/Science-And-
Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.
aspx.”
23.  In Appendix 4, mathematical symbols have been changed in several Evidence Statements in 
ways that make the text more concise but do not alter the meaning.
24.  In Appendix 4, for Evidence Statement No. 57, the penultimate bullet, the word “elevated” has 
been added to the beginning of the statement, “Elevated levels of uric acid, serum glutamic 
oxaloacetic transaminase, alkaline phosphatase, and glucose.”
25.  Appendix 5, which was formerly Table 3, has been created. The following changes have been 
made:
•  In the subheading “Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups,” under 
the list “Four statin benefit groups,” No. 4, the following sentence has been added: “This 
requires a clinician-patient discussion.”
•  In the subheading “Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups,” under 
letter C, "Treat level of ASCVD risk" header, “…class III or IV heart failure” has been 
changed to “…NYHA class II to IV heart failure.”
•  In the subheading “A New Perspective on LDL-C and/or Non−HDL-C Goals,” the second 
bullet, “dose” has been changed to “intensity” in 2 instances. 
•  In the third bullet, under letter B, the subheading “FH with LDL-C >190 mg/dL…” has 
been changed to “Familial hypercholesterolemia with LDL-C ≥190 mg/dL….”
•  In the subheading “Global Risk Assessment for Primary Prevention,” in the third bullet, the 
following text has been added: “….prevention of ASCVD. Other factors such as LDL-C 
≥160 mg/dL may also be considered. This gives…”
Correction
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In the article by Stone et al, “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol 
to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines,” which published 
ahead of print on November 12, 2013, and appeared in the supplement to the June 24, 2014, issue of 
the journal (Circulation. 2014;129[suppl 2]:S1–S45. DOI: 10.1161/01.cir.0000437738.63853.7a), 
a correction was required to include a missing author relationship with industry.
On page S28, in Appendix 1, Jennifer G. Robinson disclosed that she received significant 
research grant dollars from Eli Lilly not included in the original document. This information has 
been added to the “Personal Research” column for 2013. The author regrets this omission.
This correction has been made to the current online version of the article, which is available at 
http://circ.ahajournals.org/content/129/25_suppl_2/S1.full.
(Circulation. 2015;132:e396. DOI: 10.1161/CIR.0000000000000346.)
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